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ABSTRACT 
Autoimmune diseases are particularly challenging to study in human due to their complex 
multifactorial nature. In rheumatoid arthritis (RA), self-reactivity directed against joints leads 
to pain, tissue destruction and eventually invalidity if left untreated. Although there have been 
great advances in therapies over the past decades, there is still no cure. In this context, animal 
models are essential to improve our understanding of RA, identify new therapeutic targets 
and also evaluate new drugs. Unfortunately, no single model can perfectly mimic the human 
pathology. Hence, using a combination of independent models is critical to validate findings. 
The SKG arthritis model is a novel murine model in which defective central tolerance, due to 
reduced TCR signaling from a mutation in ZAP70, leads to chronic T cell driven arthritis. The 
understanding of the SKG model has grown over the years, and its use in drug discovery is 
now also steadily increasing. In this thesis, the SKG model is carefully characterized 
regarding innate immunity activation by mannan (paper I), the influence of genetic 
backgrounds (paper II), and the role of collagen type II (CII) as a potential self-antigen (paper 
III). Finally, the SKG model is used to study the regulation of arthritis by reactive oxygen 
species (ROS) (paper IV).  
Stimulation of innate immunity is essential to activate T cells and trigger chronic arthritis in 
SKG mice. In specific pathogen free (SPF) animal facilities, this can be achieved by a single 
injection of mannan, a polysaccharide extracted from S. cerevisiae. Paper I focuses on innate 
activation and the acute skin and joints inflammation it triggers in non-SKG mice. This 
manuscript highlights the importance of IL-17, potentially originating from γδ T cells, giving 
significant insight in the early phase of SKG arthritis preceding αβT cells involvement. 
Prior to this thesis, the SKG model had only been described on the BALB/c genetic 
background. In paper II, the mutation was backcrossed over more than 10 generations on 
B10.Q and B6.Q genetic backgrounds. Arthritis susceptibility is unaffected by the genetic 
backgrounds investigated, allowing the use of the SKG model on these common strains. This 
finding opens many possibilities in terms of crosses with genetically modified strains. 
Using a series of CII-specific TCR transgenic strains, paper III investigates the role of CII 
self-reactivity in the SKG model. Although CII reactivity is spontaneously observed in 
arthritic SKG mice, further increasing CII self-reactivity does not affect arthritis. In fact, 
restricting T cells repertoire to CII reactivity abolishes susceptibility to arthritis. CII reactivity 
is therefore not essential in SKG arthritis, and is likely a consequence of joints destruction.  
Finally, paper IV uses the SKG model to dissect the mechanisms of immunoregulation by 
ROS in autoimmunity. Thymic selection and T cells activation are unaffected by ROS 
deficiency. Although concentrations of anti-CII antibodies are higher in ROS deficient mice, 
the sera itself is not pathogenic. Instead, it is ROS production in the periphery, in particular 
from macrophages, which mediates immunosuppression in SKG arthritis. 
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1 IMMUNOLOGY 
 
1.1 WHAT IS IMMUNOLOGY? 
Immunology is the medical science studying the immune system in both health and diseases 
[1, 2]. Although most of its history is fairly recent, discoveries in immunology have already 
had tremendous impact in medicine. Originally, studies in immunology focused on infectious 
diseases, leading to major breakthroughs, such as vaccination, which completely changed the 
history of medicine. In more recent years, findings in immunology have greatly improved 
treatments for various inflammatory diseases (e.g. asthma, rheumatoid arthritis) [3]. The 
importance of immunology is now spreading to other fields, such as oncology, wound healing 
and even cardiology [4-8]. 
The immune system is composed of various organs and cells patrolling our body, and is 
responsible to protect the organism against diseases. The two main functions of the immune 
system is first to detect and recognize threats to the organism, and then to neutralize and 
eliminate such threats. These threats can either be of foreign origins (e.g. bacteria, viruses, 
fungus and parasites) or of intrinsic origin (e.g. tumors). The immune system is thus essential 
to protect us against both infections and cancers. Hereditary or acquired shortcoming in its 
functions lead to immunodeficiency, a state of high susceptibility to various infections and 
malignancies [9-11]. On the other hand, hyperactivity of the immune system can cause many 
diseases, including autoimmune diseases. 
For these reasons, a tight regulation of the immune system’s activity is crucial, and a good 
understanding of these mechanisms by the biomedical community has far reaching 
implications. A practical and frequent approach to describe the immune system is to divide it 
in two systems: innate immunity (section 1.2) and adaptive immunity (section 1.3) [2]. These 
two systems are however not independent. In fact, they support and influence each other. 
1.2 INNATE IMMUNITY 
Innate immunity encompasses mechanisms to both limit entry of pathogens in the organism 
and to eliminate such pathogens. The innate immune system is characterized by its ability to 
react rapidly to threats. This is possible because it relies on recognition of infectious agents 
through pathogen-associated and damage-associated molecular patterns (PAMPs and 
DAMPs) rather than specific antigen recognition requiring antigen processing and subsequent 
clonal expansion like in T cells and B cells responses (section 1.3). 
1.2.1 Epithelial surfaces 
Serving as frontiers between the organism and a hostile environment, the skin, the gut and the 
lungs are all frequently exposed to infectious agents. Epithelial surfaces of these organs serve 
as the first line of defense since pathogens need to bypass them to reach internal organs. 
Through mechanical (e.g. tight junctions) and chemical mechanisms (e.g. fatty acids, 
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digestive enzymes, antibacterial peptides), these organs limit access, implantation and short 
term survival of infectious agents [12, 13]. Moreover, the presence of commensal microflora 
in the gut and the skin limits implantation of pathogens by direct competition for space and 
nutrients [14, 15]. The impact of the gut microflora on the immune system is however much 
more complex than this, as it was shown to affect the development of the immune system, 
and even to modulate the immune response [16-18]. 
1.2.2 Immunosurveillance 
Despite these mechanisms, some pathogens are bound to breach these protective layers by 
different routes, for instance following skin injury. Immunosurveillance is the constant 
surveillance by the immune system for threats to the organism such as infectious agents and 
malignant cells. This is primarily done by phagocytes, such as monocytes, macrophages and 
dendritic cells (DC), which discriminate self from non-self through PAMPs recognition, and 
danger through DAMPs recognition [19]. Natural killer (NK) cells also participate in 
immunosurveillance, however their activation rely mostly on the missing-self mechanism, 
and the presence of DAMPs [20, 21]. 
1.2.2.1 Pathogen-associated molecular patterns (PAMPs) 
PAMPs are highly conserved molecular patterns specific to a family of pathogens, and which 
are usually essential for their survival. A classic example is lipopolysaccharides (LPS), an 
endotoxin found in the outer membrane of gram-negative bacteria [22].  
1.2.2.2 Damage-associated molecular patterns (DAMPs) 
In contrast, the danger model proposes that rather than discrimination of self and non-self, the 
immune system discriminates between safe and dangerous situations using “alarm signals” 
from injured or stressed tissues [23]. These include DAMPs, host molecules such as nuclear 
or cytoplasmic proteins, often released in the extracellular fluids upon cell necrosis [24]. A 
well-characterized DAMP is the chromatin-associated protein high-mobility group box 1 
(HMGB1) [25, 26]. 
1.2.2.3 Mannan 
An important PAMP for this thesis is mannan, a fungal polysaccharide extracted from the cell 
wall of yeast (e.g. C. albicans and S. cerevisiae). The structure consists of a backbone of 
α-(1,6)-linked mannose with α-(1,2) and α-(1,3) side chains [27]. Several receptors were 
found to bind mannan, including the mannose receptor, dectin 2, TLR4 and DC-SIGN [28-
31]. It activates monocytes, macrophages and DCs to produce cytokines supporting mostly 
Th17 differentiation, and also to a lower extent Th1 [32-34].  
1.2.2.4 Pattern recognition receptors (PRRs) 
Both PAMPs and DAMPs are recognized by pattern recognition receptors (PRRs) [19, 24]. 
These receptors include toll-like receptors (TLRs), NOD-like receptors and C-type lectin 
receptors [35, 36]. Activation of PRRs is a key event leading to cytokines production 
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necessary to activate and modulate both innate and adaptive immunity to respond 
appropriately to various sources of threats.  
Monocytes are among the innate cells expressing PRRs. Upon recognition of pathogens 
through the activation of PRRs, monocytes engulf them. Some monocytes then differentiate 
into macrophages [37]. Others will differentiate in DC and start migration towards the 
draining lymph node (dLN) [38]. During this transit, DC will further mature by upregulating 
co-stimulatory molecules such as CD80 and CD86 [39]. Upon arrival in the dLN, cell 
maturation is over and DC are able to present to T cells various antigens from the digested 
pathogen, while also expressing the necessary co-stimulatory molecules required to activate 
naïve T cells.  
1.2.3 Antigen presentation 
Antigen presentation by innate cells is an important link between innate and adaptive 
immunity. Every nucleated cell constantly presents intracellular antigens on major 
histocompatibility complex (MHC) class I [1]. This is a general mechanism of surveillance 
against intracellular infections and mutations. Down-regulation of MHC-I, for instance by 
virus as an escape mechanism, will lead to activation of NK cells due to the lack of inhibitory 
signal from self-MHC (the missing-self theory). Antigen-presenting cells (APC) also have the 
ability to present antigens from extracellular sources, for example phagocytosed bacteria, on 
MHC-II. This mechanism is important for the defense against extracellular infectious agents. 
Professional APCs, such as DCs, also express co-stimulatory molecules.  
1.2.4 Macrophages 
Macrophages are tissue resident cells with a wide variety of functions [2, 40]. In recent years, 
researchers have highlighted the complexity and diversity of the different macrophage 
populations. A common classification is the distinction between M1 and M2 macrophages 
[41]. Whereas M1 macrophages are implicated in host defense and are thus considered 
pro-inflammatory, M2 macrophages favor tissue repair and have potent anti-inflammatory 
proprieties [42]. Originally, the classification in classically activated M1 and alternatively 
activated M2 was proposed due to the parallel with the Th1/Th2 paradigm (section 1.3.7.2 - T 
helper lymphocytes), where M1 are associated to IFN-γ, and M2 to IL-4, IL-13 and IL-10 
(Figure 1) [43, 44]. This classification is however not a true dichotomy, and polarization is 
partly reversible [43, 45]. More recent classifications generally also include wound-healing 
macrophages. 
As mentioned previously, an important function of macrophages is immunosurveillance of 
tissues for threats, and the subsequent phagocytosis of pathogens. The cytokines and 
chemokines they release following the activation of PRR are essential to attract leukocytes 
from the blood, such as T cells, to help fight the infection. Due to their expression of MHC-II, 
macrophages can present antigens to activated T helper (Th) cells in inflamed tissue (section 
1.3.7.2 - T helper lymphocytes). This interaction is essential to cytokines release from Th, 
which triggers the digestion of phagosomes by macrophages and causes an influx of effector 
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cells including neutrophils. Macrophages express the NADPH oxidase 2 (NOX2) complex, 
producing large amount of reactive oxygen species (ROS) which are used in the digestion of 
phagocytosed pathogens [46].  
 
 
Figure 1 - Interactions between macrophages and T cells 
Key mediators involved in macrophages-T cells interactions from classically activated 
macrophages (a), regulatory macrophages and wound-healing macrophages (b). 
Whereas pro-inflammatory Th1 and Th17 are associated to classically activated 
macrophages (M1), both Treg and Th2 are associated to regulatory and wound-healing 
macrophages (M2). 
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2008. 8(12): p. 958-69. 
Copyright (2008). 
 
1.2.5 Neutrophils 
Neutrophils are fast acting effector cells of the innate immune system. In healthy state, a large 
population of neutrophils already circulates in the blood to facilitate rapid deployment in 
inflamed tissues. Inflammation further increases the concentration of circulating neutrophils. 
Upon detection of inflammation (e.g. chemokines and cytokines), neutrophils rapidly migrate 
to inflamed tissue via adhesion molecules expressed on endothelial cells [47]. Chemokines 
gradients direct the cells towards the threats where neutrophils will attack pathogens [48]. 
The action of neutrophils is meant to be fast; therefore they store large amounts of mediators 
in granules. 
Depending on the duration and strength of stimulation, they will release primary granules 
(azurophilic) containing myeloperoxidases, defensins, elastases and phospholipases (A2, C 
and D) [49, 50]. Phospholipases in primary granules are implicated in the synthesis of lipid 
mediators which are potent but short lived inflammatory mediators (e.g. LTB4 and PAF). 
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Secondary granules contain lactoferrin and lysozyme, whereas tertiary ones contain 
collagenases. Finally, neutrophils also produce large amount of ROS via the NOX2 complex 
[46, 51]. 
Enzymes and mediators released by neutrophils are very potent to fight infections, but they 
can also damage host tissues [52]. To prevent prolonged uncontrolled inflammation, the 
survival of neutrophils in inflamed tissues is limited as they undergo programmed cell death 
relatively quickly after leaving the blood [53]. Hence, a constant influx of neutrophils 
dependent on cytokines and chemokines from various sources (e.g. T cells) is required until 
the threat is fully neutralized. 
 
Figure 2 - Cellular redox biology 
Cellular ROS originates from various sources (indicated in red). Superoxide (O2
-
) is 
generally the original free radical produced. It can then be converted to hydrogen 
peroxide (H2O2) by superoxide dismutases (SOD). H2O2 is relatively stable, membrane 
permeable and it can be converted to water by peroxiredoxins and glutathione 
peroxidase when in low concentrations, or to water and oxygen by catalase at high 
concentrations. In the presence of free heavy metal (such as Fe
2+
), H2O2 can also be 
converted to hydroxyl radicals (HO ) through the Fenton reaction. HO  is highly 
reactive and toxic, reacting with lipids, proteins and DNA. Major ROS-scavenging 
enzymes are shown in green. GPX, glutathione peroxidase; GR, glutathione reductase; 
GRXo, glutaredoxin (oxidized); GRXr, glutaredoxin (reduced); GSHr, glutathione 
(reduced); GSSG, glutathione (oxidized); TRXo, thioredoxin (oxidized); TRXr, 
thioredoxin (reduced); XO, xanthine oxidase. 
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Drug Discov, 2009. 8(7): p. 579-91. 
Copyright (2009). 
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1.2.6 Reactive oxygen species (ROS) 
ROS are a group of highly reactive molecules derived from oxygen. They can originate from 
both exogenous and endogenous sources. Redox biology studies the physiological and 
pathological effects of the reduction–oxidation balance which depend on the location, 
duration and exact molecular nature of various ROS [54]. Oxidation of cysteine residues due 
to variations in the redox balance modifies proteins conformation and activity [55]. Cell 
permeability, reactivity, half-life and toxicity vary greatly among various ROS. Figure 2 
presents the homeostasis of cellular ROS. 
1.2.7 NADPH oxidase 2 (NOX2) 
NOX2, also referred to as the phagocyte NADPH oxidase, is responsible for respiratory burst 
of neutrophils and macrophages [46, 56]. Cellular activation of neutrophils upon detection of 
microorganisms or pro-inflammatory mediators results in the activation of the NOX2 
complex and the production of large amount of O2
-
. According to the current model of NOX2 
activation, Ncf1 (also known as p47
phox
) serves as organizer subunit. Upon phosphorylation, 
p47
phox
 interacts with p22
phox
, leading to the translocation of other cytosolic factors such as 
the activator subunit p67
phox 
to the catalytic subunit GP91
phox
 (Figure 3) [57]. Without the 
organizer subunit p47
phox
, the NOX2 complex cannot recruit the activator subunit and is 
therefore dysfunctional [58]. Other NOX complexes have been identified in several other cell 
types, but NOX2 is by far the most potent. 
 
 
Figure 3 - Activation of the NOX2 complex 
In resting neutrophils, the NOX2 complex is inactive. Upon cellular activation, 
phosphorylation of p47
phox
 leads to the translocation of p22
phox
 and p67
phox
 to the 
catalytic subunit gp91
phox
. The assembled NOX2 complex then generates high amounts 
of O2
-
. 
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2004. 4(3): p. 181-9. 
Copyright (2004). 
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1.3 ADAPTIVE IMMUNITY 
Whereas innate immunity relies on recognition of group of pathogens through class-specific 
molecular motives, adaptive immunity is antigen-specific, meaning that it is slower due to the 
requirement for antigen processing and clonal expansion. The other key feature of adaptive 
immunity is memory [59]. The main components of adaptive immunity are B cells that 
produce antibodies, and T cells that either directly kill cells, produce cytokines to orchestrate 
the immune response or assist B cells in antibody production. The work in this thesis 
primarily concerns T cells; therefore they will be the focus of this section.  
1.3.1 T cell development 
In the bone marrow, the hematopoietic stem cells divide to give rise to the common lymphoid 
progenitor, which is the source of T cells, B cells, innate lymphoid cells and NK cells [2]. At 
some point during differentiation, some cells leave the bone marrow through systemic 
circulation and reach the thymus, a central lymphoid organ where T cells development and 
selection occur. Following signaling by stromal cells, these cells commit to T cell lineage 
[60]. After differentiation in the thymus, they start proliferating to generate the very high 
number of thymocytes required to have sufficient T cells output considering that 
approximately 97% of thymocytes undergo apoptosis during the followings steps of 
development [61, 62].  
1.3.2 T cell receptor (TCR) 
A key feature of adaptive immunity and T cells is the generation of a large repertoire of cells 
with unique specificity. This is possible because each T cell is restricted to a unique T cell 
receptor (TCR), with affinity for a specific antigen presented by a specific MHC molecule. 
The TCR is a membrane-bound heterodimer composed of either α- and β-chains (~95%), or 
γ- and δ-chains (~5%). Although they are both technically “T cells”, the biology, the 
development and the functions of so called αβT and γδT cells are very different and should 
not be confused. Unless specifically mentioned, the term “T cells” is usually used in literature 
and in this thesis to refer to αβT cells, whereas γδT cells are always referred specifically as 
γδT cells. 
1.3.3 V(D)J recombination 
The large repertoire of TCR poses an interesting challenge: the number of potential unique 
TCR molecules is too large for them to be included as single genes in the genome. Instead, to 
create this vast library of unique TCR, a limited set of interchangeable genes are encoded in 
the genome. In thymocytes, the different regions of these genes are recombined in a process 
called V(D)J recombination during which the TCR loci are re-arranged in a semi-randomized 
process giving rise to different clones, each expressing a TCR with unique specificity [1, 63]. 
Figure 4 is a schematic representation of both β- and α-chain re-arrangements [64]. 
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Figure 4 - V(D)J recombination of α- and β-TCR chains 
Somatic gene recombination of variable (V), diversity (D) and junctional (J) gene 
segments of first the β-chain, and then the α-chain, generates the vast diversity of 
unique TCR. Complementarity-determining regions (CDRs) are hypervariable regions 
determining specificity. 
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2006. 6(12): p. 883-94. 
Copyright (2006). 
 
During V(D)J recombination, the variable region of the TCR chains, which is the binding site 
determining specify towards the MHC-peptide complex, is re-organized starting with TCRβ 
and later TCRα. The various variable (V), diversity (D) and joining (J) genes included in the 
genome are randomly joined to create unique TCR. Further increasing the diversity of the 
resulting re-arranged genes is the terminal deoxynucleotidyl transferase (TdT) that introduces 
randomly additional nucleotides when reattaching the DNA strains [65, 66].  
The recombination-activating genes (RAG)-1 and -2 are essential enzymes for V(D)J 
recombination [67, 68]. A similar process also dependent on RAG molecules occurs in B 
cells with their B cell receptor (BCR). Hence, mice deficient in RAG lack both T cells, B 
cells, and any other non-classical cells also requiring re-arrangement, such as NKT cells and 
γδT cells [69, 70]. 
1.3.4 TCR signaling  
The TCR is composed of a variable region responsible for binding the MHC-peptide 
complex, and a constant region associated to signaling molecules [71-73]. The TCR interacts 
with the MHC-peptide complex, while the co-receptors CD4 or CD8 and adhesion molecules 
help at the formation of a stable interaction. Upon binding, the co-receptors help recruiting 
the tyrosine kinase Lck which phosphorylates ITAMs motives of CD3 chains [74]. This 
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phosphorylation allows the recruitment and phosphorylation by Lck of the zeta-chain 
associated protein kinase 70kDa (ZAP70) [75]. ZAP70 then phosphorylates key residues of 
the linker for activation of T cells (LAT), leading to LAT signalosome formation and 
subsequent signal transduction by three branches: Ca
2+
 influx, MAPK and NF-κB (Figure 5) 
[71].  
 
 
Figure 5 – TCR signaling pathways 
Phosphorylation events following recognition of the MHC-peptide complex by the 
TCR leading to T cell activation. Phosphorylation of ITAM motives on CD3 favors the 
recruitment of ZAP70 that then phosphorylates LAT, leading to subsequent 
intracellular signaling. 
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2013. 13(4): p. 257-69. 
Copyright (2013). 
 
1.3.4.1 ZAP70 
ZAP70 is a tyrosine kinase that has an essential role in signal transduction through the TCR 
signalosome. The association of ZAP70 to CD3 ζ-chains is a crucial step in T cell signaling, 
and happens within seconds of antigen recognition by the TCR [76]. Whereas thymocytes in 
early stages of development also express spleen tyrosine kinase (Syk) for signal transduction, 
mature T cells solely rely on ZAP70, making it a central protein in T cell activation [77]. 
Loss of function in human leads to severe combined immunodeficiency characterized by the 
absence of peripheral CD8
+
 T cells, and normal number of nonfunctional CD4
+
 T cells [78, 
79]. In mice however, thymocytes development is completely blocked at the double positive 
(DP) stage in ZAP70
-/-
, resulting in an absence of both CD4
+
 and CD8
+
 T cells in the 
periphery [80]. This distinction might be explained by a different expression of Syk and 
ZAP70 during the development of CD4
+
 T cells. Nevertheless, the lack of function of CD4
+
 T 
cells in human demonstrates the essential role of ZAP70 in mature T cells. 
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Although it is usually associated to T cell activity due to this non-redundant role, other 
immune cells also express ZAP70. In these cells, ZAP70 is also responsible for signal 
transduction of membrane receptors bearing ITAM motives (e.g. FcRγ, BCR, and killer 
cell-activating receptor-associated protein (KARAP)) [20, 81]. It was described in mice and 
human B cells depending on cellular maturity, and in human B cells malignancies such as 
chronic lymphocytic leukemia [82]. Expression of ZAP70 in B cells is associated to increased 
BCR signaling [83]. However, unlike in mature T cells, B cells signal transduction relies 
mostly on Syk [84]. On the other hand, NK cells rely on both Syk and ZAP70, with 
noticeable reduction in activity only in double knockout mice, in which cytotoxicity is not 
even completely abolished due to several redundant activation pathways [81, 85]. 
1.3.5 T cell selection 
The great advantage of the random re-arrangement of TCR is that it allows recognition of a 
vast library of antigens without a need for each specific TCR to be included in the genome. 
This library is so vast that virtually any peptides presented by an MHC molecule could be 
recognized by a specific TCR. However, this also leads to the generation of both 
non-functional and self-reactive T cells. Whereas the organism would waste resources 
keeping non-functional T cells, self-reactive T cells are potentially harmful. The purpose of T 
cell selection is to keep only T cells expressing a functional TCR but that do not react against 
self-antigens. These selections processes are respectively called positive and negative 
selections [80, 86]. 
Selections occur in the thymus, in which T cells follow several steps of maturation (Figure 6) 
[87, 88]. Lymphoid progenitors enter the cortex of the thymus when they are at the double 
negative 1 (DN1) stage, meaning that they are negative for both CD4 and CD8, and are 
CD44
+
CD25
neg. The β-chain is first rearrange, and from DN3 to DN4, successful pre-TCR 
signaling is required for survival. At this stage, thymocytes rely on both ZAP70 and Syk for 
signal transduction. At the DP stage, thymocytes express both CD4 and CD8, and have now 
re-arranged both the α- and the β-chains. Positive and negative selections then occur in the 
medulla. Positive selection is the requirement of successful TCR signaling for survival 
following recognition of self-MHC [89]. Negative selection is the removal of clones highly 
reactive to self-antigens, a process dependent on the presentation of self-antigens in the 
thymus by APC such as mTEC [90, 91]. Ectopic expression of tissue-restricted self-antigens 
in the thymus by various mechanisms, including a critical role of AIRE, is essential to central 
tolerance [92]. Both positive and negative selections are dependent on TCR signaling 
strength, which is proportional to the affinity between the MHC-peptide complex and the 
TCR. At this stage, TCR signaling relies solely on ZAP70 since thymocytes lost expression 
of Syk [77]. 
1.3.6 T cell activation 
Naïve T cells, which have never encountered their antigen, circulate in the blood and travel to 
various lymph nodes where APC constantly present antigens. TCR recognition of the 
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MHC-peptide complex is the first step towards activation. CD4 or CD8 serve as co-receptor, 
binding either MHC-II or MHC-I respectively, and help to recruit Lck which is needed for 
TCR signaling [93, 94]. A second signal is however essential, otherwise T cells become 
anergic. This secondary signal, referred to as co-stimulation, relies on the expression of 
co-stimulatory molecules by professional APC [95]. The most carefully characterized are the 
activating CD80-CD86/CD28 and the inhibitory PD-1/PD-L1, however many others have 
also been described [96]. Inhibitory molecules have drawn a lot of attention due to their 
involvement in cancer immunoevasion. These findings led to the recent approval of 
checkpoint inhibitors for cancer immunotherapy [97]. Finally, the cytokines 
microenvironment, which is considered by some immunologists as a third signal, tailors T 
cells differentiation [98, 99].  
 
 
Figure 6 – T cell development in the thymus 
The various steps of maturation of thymocytes from lymphoid progenitors to mature SP 
T cells, including positive and negative selections.  
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2002. 2(5): p. 309-22. 
Copyright (2002). 
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The organization of the various binding molecules during APC/T cell interaction is referred 
to as the immunological synapse [100-102]. Organization of receptors in lipid rafts is 
important for its formation [103]. Other than signaling molecules, the immunological synapse 
also includes adhesion molecules (e.g. ICAM-1, LFA-1) stabilizing the interaction between 
both cells. 
1.3.7 Effector functions of T cells 
Two subsets of αβT cells can be distinguished based on their expression of CD4 or CD8 
co-receptors. Whereas CD8
+
 T cells recognize intracellular peptides presented on MHC-I, 
CD4
+
 T cells recognize extracellular peptides presented on MHC-II [2]. This distinction is 
important to understand the difference in their functions. 
1.3.7.1 Cytotoxic T lymphocytes (CTL) 
CD8
+
 T cells, also called cytotoxic T lymphocytes (CTL), induce apoptosis of the presenting 
cell. Once activated CTL detect their antigen on a cell, they release granules containing 
perforin and granzymes, leading to membrane permeation and apoptosis of the targeted cell 
[1]. CTL also induce apoptosis through Fas/FasL interaction, as well as TRAIL/TRAIL-R. 
Since all nucleated cells express MHC-I and constantly present cytosolic antigens, this 
mechanism insures that compromised cells, either from infection or malignancy, are 
eliminated promptly to contain the risk. 
1.3.7.2 T helper lymphocytes (Th) 
On the other hand, CD4
+
 T cells recognize extracellular antigens presented on MHC-II, 
meaning that the presenting cell is not necessarily compromised, but rather the surrounding 
environment. The role of CD4
+
 T cells, referred to as T helper cells (Th), is to orchestrate an 
immune response appropriate to the pathogen itself. To do so, Th secrete at the site of 
inflammation chemokines to attract the appropriate cells, and cytokines to elicit cellular 
response. Cytokines secreted by innate cells in response to DAMPs/PAMPs will fine-tune the 
differentiation of Th in different subsets, which in turns secrete a different set of cytokines. 
Common nomenclature divides Th into Th1, Th2, Th17 and regulatory T cell (Treg) (Figure 
7) [104-106]. 
Activation of the transcription factor T-bet following exposure to IL-12 and IFN-γ leads to 
differentiation into Th1 [107]. A Th1 response is characterized by the secretion of IFN-γ and 
IL-2, which activate macrophages and favor phagocytosis of pathogens. This response is 
particularly important against intracellular pathogens, but it is also considered 
pro-inflammatory and would be associated to autoimmune diseases [108]. 
Th2 differentiation is under the control of the transcription factor GATA-3, which is activated 
in response to IL-4 [109]. Th2 secrete IL-4 and IL-5 to induce B cells proliferation and help 
humoral response [110]. These Th2 cytokines are associated to parasite infections, such as 
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helminths, and are implicated in allergic reaction and asthma [111-113]. Th2 cytokines also 
exert anti-inflammatory and wound healing effects.  
 
 
Figure 7 – Differentiation of CD4+ T cells in various subsets of effector cells 
Following activation by APC, the cytokines microenvironment influences the 
differentiation of CD4
+
 T cells in 4 subsets of effector cells.  
Adapted with permission from Macmillan Publishers Ltd: Nat Rev Immunol, 2010. 10(4): p. 248-56. 
Copyright (2010). 
 
More recently, a subset of Th producing IL-17 was identified [114, 115]. This finding totally 
changed the Th1/Th2 paradigm [116]. Their implication in autoimmunity has also steered a 
debate regarding the implication of either Th1 or Th17 in these diseases [117]. Other than 
IL-17, their production of GM-CSF is also contributing to autoimmunity [118]. Th17 
differentiation is under the control of the transcription factor ROR-γt, which is activated in 
mice by TGF-β and IL-6 [119]. Although it does not seem to affect directly the commitment 
to Th17 lineage, IL-23 has an important role in the maintenance of Th17 [120]. Th17 are 
implicated in the clearance of extracellular infections such as fungi by the recruitment of 
inflammatory cells like neutrophils [121, 122]. 
Finally, a subset of CD4
+
 T cells differentiate into Treg following the induction of the 
transcription factor Foxp3 [123, 124]. These cells have immunosuppressive functions. They 
can either originate from thymic development (natural Treg, nTreg) or be induced by 
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cytokines such as TGF-β in the periphery (induced Treg, iTreg) [125]. Regarding 
immunosuppressive mechanisms, Treg are known to secrete IL-10 and TGF-β, which could 
explain immunomodulation from soluble factors. Treg also express high level of CD25, the 
high affinity receptor for IL-2. Another regulatory mechanism involves the critical role of 
CTLA-4 [126, 127]. Finally, it is worth mentioning that TCR signaling is needed by Treg for 
proper immunosuppressive activity [128].  
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2 AUTOIMMUNE DISEASES 
Autoimmune diseases are a family of diseases which share a similar pathogenesis; the 
activation of the immune system against self-antigens. Classification of common autoimmune 
diseases traditionally focused on affected organs: psoriasis (skin), rheumatoid arthritis 
(joints), type I diabetes (beta islets of the pancreas), multiple sclerosis (central nervous 
system), Crohn’s disease (gastrointestinal tract) and ulcerative colitis (distal colon) [129-133]. 
2.1 PSORIASIS 
Psoriasis is an autoimmune disease of the skin with a prevalence of approximately 2% [134]. 
Like many other autoimmune diseases, both genetic predispositions and environmental 
factors contribute to its onset [135-137]. It is characterized by erythematous plaques covered 
by white scales. Psoriatic lesions are characterized by hyperplasia and incomplete 
differentiation of keratinocytes in the epidermis, accumulation of leukocytes in the skin and 
increased angiogenesis [130]. Approximately one third of patients also suffer from associated 
joints inflammation, a disease called psoriatic arthritis [138, 139]. 
2.1.1 Epidemiology of psoriasis 
Epidemiologic studies reveal that prevalence varies between ethnic groups, with higher 
prevalence among Caucasians, and lower prevalence among Japanese, aboriginal from 
Australia and South America [140, 141]. The first symptoms can appear at different ages. 
However, two peaks of onset are described; early onset between 20 and 30 years, and late 
onset between 50 and 60 years [142, 143]. 
2.1.2 Genetics of psoriasis 
The contribution of genetic predispositions to psoriasis susceptibility has long been known 
due to the higher prevalence within the same family [144, 145]. Studies in twins indicate an 
increased prevalence in monozygotic twins, demonstrating the importance of genetics. 
However, the concordance of only 30% demonstrates the major role of environmental factors 
in psoriasis onset [146, 147]. Nowadays, large genome-wide association studies have 
identified 36 risk loci [135, 148]. Most genes are implicated in the immune response, but 
some are also associated to barrier development of the skin [149].  
The strongest association is found within HLA-C, which suggests a role for T cells in this 
pathology [150, 151]. Other major risk loci associated to T cells include IL12B and IL23R 
[152, 153]. The implication of these cytokines suggests biased differentiation of Th to pro-
inflammatory phenotype through the IL-23/Th17 axis [154, 155]. Finally, it is interesting to 
note that polymorphism in the protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 
was associated to early onset psoriasis, a gene that is also strongly associated to other 
autoimmune diseases, including RA [156, 157]. 
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2.1.3 Disease mechanisms of psoriasis 
There are three main components in the pathogenesis of psoriasis: epidermis alterations, 
activation of the immune system, and angiogenesis [130]. All three components interact 
closely, for instance increased angiogenesis and leaky blood vessels contribute to the 
accumulation of leukocytes. These leukocytes secrete cytokines, which affect growth and 
differentiation of keratinocytes within the skin, leading to hyperproliferation and chemokines 
secretion which further increase recruitment of leukocytes and angiogenesis [158]. Figure 8 
illustrates mechanisms proposed by Nestle et al. 2009 of initiation and maintenance of 
psoriatic lesions [134]. 
2.1.3.1 Epidermis 
Hyperplasia of keratinocytes in the epidermis is characteristic of psoriatic lesions. The basal 
cells divide on average every 40 hours in psoriatic lesions, instead of 200 hours in healthy 
skin [159]. This rapid turnover leads to incomplete differentiation and maturation of 
keratinocytes, affecting the integrity of the skin [160]. Keratinocytes normally lose their 
nucleus during differentiation in the stratum corneum of healthy skin, however in psoriatic 
lesions, nucleuses are often observed, a phenomenon called parakeratosis that is indicative of 
incomplete differentiation [161]. This incomplete differentiation is also reflected by the 
keratin produced in psoriatic lesions, which are mostly K6/16 and K17 rather than K1/10 
normally associated to terminally differentiated keratinocytes [162, 163].  
2.1.3.2 Immune response 
As mentioned previously, genetic predispositions strongly support the implication of the 
immune system and the IL-23/Th17 axis [164, 165]. Numerous animal models and therapies 
also support a role for T cells [166, 167]. Moreover, recent drug development has focused on 
controlling aberrant T cells activity in psoriatic lesions [168]. For example, cyclosporine A, 
which is an immunosuppressive drug inhibiting calcineurin and thus reducing the production 
of IL-2, is used to treat severe psoriasis [169]. More recently, drugs directly targeting the 
IL-17/IL-23 pathway were approved. Other immune cells also have a role in the development 
of skin lesions, including cells of the innate immunity. For example, it was demonstrated that 
neutrophils were essential in the flaky skin mice model to develop skin lesions [170]. 
Moreover, a case report in human describes the resolution of psoriasis during agranulocytosis 
in a patient receiving ticlopidine, and the later relapse of skin lesions upon normalization of 
circulating neutrophils [171]. The importance of the IL-17/IL-23 pathway corroborates with 
an implication of neutrophils in psoriasis development.  
2.1.3.3 Angiogenesis 
The importance given to angiogenesis in the pathogenesis of psoriasis has increased in the 
past few years, some authors even suggesting it to be a driving factor rather than a 
consequence of skin inflammation [172]. Most of the approved drugs to treat psoriasis affect 
either directly or indirectly blood vessels [173]. The excessive angiogenesis is the result of 
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increased local concentrations of vascular endothelial growth factor (VEGF) [174-176]. 
Interestingly, transgenic mice expressing constitutively VEGF in the basal layer of the 
epidermis had both increased angiogenesis, and also increased adherence and recruitment of 
leukocytes in the skin [177]. 
 
 
Figure 8 – Mechanisms of psoriasis from initiation to maintenance  
Schematic representation of the evolution of psoriatic lesions proposed by Nestle et al. 
2009 [134]. In individual genetically predisposed to psoriasis, environmental factors 
will trigger activation of innate immunity in the skin. APC then migrate to dLN where 
activation of Th1 and Th17 occur. Recruitment of activated T cells in lesions and 
secretion of cytokines perpetuated the activation and hyperproliferation of 
keratinocytes, and the expansion of blood vessels.  
Reproduced with permission from N Engl J Med, 2009. 361(5): p. 496-509. Copyright Massachusetts 
Medical Society. 
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2.1.4 Treatments of psoriasis 
Although lesions can be treated, there is currently no cure for psoriasis [178]. Patients will 
therefore experience remissions and relapses throughout their life, significantly decreasing 
their quality of life [179, 180]. A complete description of psoriasis treatments and clinical 
guidelines is outside the scope of this thesis; however it is worth mentioning that most novel 
therapies focus on controlling the immune system rather than controlling directly the 
proliferation of keratinocytes. The use of biologic drugs in the past two decades has 
drastically improved the treatment of patients suffering from severe psoriasis. The most 
commonly used biologic drugs are TNF-α blockers, which have now been used for almost 
two decades [181, 182]. More recently, two other monoclonal antibodies targeting IL-12/23 
(ustekinumab) and IL-17 (secukinumab) were approved by the FDA for the treatment of 
severe psoriasis, highlighting once again the importance of Th17 in the pathogenesis of 
psoriasis [134, 183, 184]. 
2.2 RHEUMATOID ARTHRITIS (RA) 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation 
and progressive destruction of joints. It affects approximately 1% of the worldwide 
population [131]. RA is not only reducing life quality of patients: it is also the leading cause 
of disability in the US, representing a significant societal burden through both high direct 
(e.g. treatments) and indirect costs (e.g. loss of productivity) estimated at $128 billion in 2003 
[185-187]. Its exact pathogenesis remains unknown, however genome-wide association 
studies have now identified more than 100 risk loci, and several environmental factors have 
been associated to RA [188-190]. A better understanding of the immunopathogenesis of RA 
has helped improve drastically treatments over the past two decades. Animal models of 
arthritis have been central to these developments, and remain essential to discover and 
investigate novel therapeutic targets.  
2.2.1 Diagnosis 
In 2010, the American College of Rheumatology and the European League Against 
Rheumatism published a new guideline to help clinicians diagnose RA [191]. Table I presents 
their scoring system based on the number of affected joints, the duration of symptoms, and 
serologic markers. A diagnosis of RA is defined as a score of 6 points or more. Interestingly, 
this updated guideline introduced antibodies to citrullinated protein antigens (ACPAs) as 
diagnosis criteria of RA. Extensive research is still conducted to further identify biomarkers 
for diagnosis and prognosis of RA. 
2.2.2 Antibodies to citrullinated protein antigens (ACPAs) 
The discovery and association of ACPAs to RA has been a major breakthrough in the field. 
This association had been described long before the publication of the 2010 guideline [192, 
193]. Interestingly, APCAs can be detected many years before the apparition of symptoms 
[194, 195]. They also have a prognosis value, being associated to more severe radiologic 
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damage in the joints [196, 197]. The direct pathogenicity of these antibodies remains unclear 
and somewhat controversial, some groups claiming that they either enhance or even induce 
arthritis in rodents, whereas others could not reproduce these findings [198-200]. 
Nevertheless, ACPAs association to RA is undeniable, and suggests immunological 
abnormalities long before clinical onset. 
 
Table I - The ACR/EULAR 2010 classification for RA 
    Criteria Score 
A. Joint involvement:  
     1 large joint 0 
     2-10 large joints 1 
     1-3 small joints (with or without large joints involved) 2 
     4-10 small joints (with or without large joints involved) 3 
     >10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification as RA):  
     Negative RF and negative anti-CPP antibodies 0 
     Low-positive RF or low-positive anti-CPP antibodies ( ≤ x3 upper normal limit) 2 
     High RF or high anti-CPP antibodies ( > x3 upper normal limit) 3 
C. Acute phase reactants:  
     Normal CRP level and normal ESR 0 
     Abnormal CRP level or abnormal ESR 1 
D. Duration of symptoms:  
     < 6 weeks 0 
     ≥ 6 weeks 1 
Note: To be applied only to patients: (1) who have at least 1 joint with definite synovitis, excluding the DIP 
joints, first MTP joints, and first CMC joints, and (2) in whom the synovitis cannot be explained by another 
disease. Definite RA is defined as a cumulative score of 6 points or more (max 10).  
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It is often suggested that RA should be divided in ACPA
+
 and ACPA
neg
, a distinction of 
importance in genetic studies since the risk factors associated to those two subtypes are likely 
to differ significantly [201-203]. Reclassification of diseases based on biomarkers and 
pathogenesis, rather than anatomy and symptoms, is a common trend in modern medical 
research, in particular in oncology (e.g. HER2
+
 breast cancer) because it affects therapeutic 
strategies. The discovery of ACPAs has not only helped in the diagnosis and prognosis of 
RA, but it has also helped researchers to investigate novel disease mechanisms leading to 
several interesting hypotheses explaining various genetic and environmental risk factors.  
2.2.3 Epidemiology of RA 
Prevalence of RA varies geographically; higher prevalence being observed in Northern 
Europe and North America compared to South America, Asia and Africa [204]. The 
prevalence is particularly high among Native Americans, reaching up to 7% in certain groups 
[205]. Women are 2 to 3 times more likely than men to have RA [204, 206]. The first 
symptoms of RA can appear at various ages, with a peak of incidence at around 50 years old 
[207]. It is worth mentioning again that immunological changes, such as production of 
self-reactive antibodies, can precede the diagnosis of RA by up to 10 years [194, 195, 208, 
209].  
2.2.4 Genetics of RA 
Genetic predispositions have an important role in the development of RA. Family history is a 
major risk factor to develop RA, with a calculated heritability of 65% [210]. Studies in twins 
revealed a concordance of approximately 15% and 4% in monozygotic and dizygotic twins 
respectively, a clear increase compared to baseline prevalence. Still, the low concordance 
highlights the importance of gene-environment interactions to trigger the disease [211, 212]. 
It also suggests that prevention is possible since genes by themselves are not sufficient. 
More than 100 risk loci have now been identified by genome-wide association studies [188, 
189, 213]. Most loci identified are believed to affect the immune system, and are frequently 
associated to T cells activity. Considering the high number of risk loci and their relatively low 
contribution to RA (e.g. OR 1.05), this section will focus on the two most important loci, 
which are also directly relevant to the work presented in this thesis. 
2.2.4.1 HLA-DRB1 
By far, the most important genetic contribution is within the MHC region, which contributes 
for more than all other risk loci identified taken altogether [189]. Several susceptibility alleles 
have been identified, the most characterized within the HLA-DRB1*04 group [214]. The 
shared epitope hypothesis claims that the amino acid sequence 70-74 from the HLA-DRβ 
chain is critical at conferring arthritis susceptibility [215, 216]. It is believed that the shared 
epitope is crucial in self-antigen presentation. Interestingly, an association between 
HLA-DRB1 and antibody response, in particular anti–cyclic citrullinated peptides (CPP) 
antibodies, has been found [217-219]. Major efforts to understand this link between antigen 
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presentation from disease promoting HLA alleles, posttranslational modifications and 
antibodies production have been made in the past few years [199, 220]. Studies have also 
found that disease progression is more severe in patients with both anti-CPP antibodies and a 
shared epitope allele [214, 219].  
2.2.4.2 PTPN22 
The strongest non-MHC genetic association is within PTPN22, a protein tyrosine 
phosphatase expressed primarily in lymphoid cells [221, 222]. In T cells, PTPN22 inhibits 
TCR signaling by dephosphorylating various kinases of the Src (e.g. Lck) and Syk families 
(e.g. ZAP70) [223]. Its activity relies on binding with Csk [71]. The risk allele in PTPN22 
(1858C>T) leads to a R620W substitution in the protein in one of the four proline-rich SH3 
binding sites, and was found to affect binding to Csk [223, 224]. The mutation causes a 
gain-of-function of PTPN22, and thus a reduction of TCR signaling [225, 226]. An 
interesting hypothesis regarding the mechanism of autoimmunity is that this reduction in 
TCR signaling would affect central tolerance in the thymus, leading to self-reactive T cells 
escaping deletion [222, 227]. Another hypothesis is that it affects the removal of self-reactive 
B cells [228-230]. 
The first causative hypothesis linking the mutation to autoimmunity is particularly relevant to 
this thesis due its parallel with the SKG model of arthritis. Apart from RA, this mutation is 
also strongly associated to other autoimmune diseases such as type I diabetes, systemic lupus 
erythematous, and Grave’s disease [231-234]. The association of this allele with various 
autoimmune diseases is in accordance with an unspecific mechanism of break of tolerance 
such as the defective thymic selection hypothesis or the B cells hypothesis. 
2.2.5 Environmental risk factors of RA 
As with most autoimmune diseases, RA is a complex multifactorial disease in which both 
genes and environmental factors contribute to disease onset. A common view is that 
environmental factors can trigger a chain of events leading to RA, but only in individuals 
with particular genetic predispositions. 
2.2.5.1 Smoking 
Smoking has long been suggested as an environmental risk factor to RA based on 
epidemiologic studies [235-238]. Interestingly, a study in discordant twins also supports this 
association, however the sample size was relatively small [239]. Data also suggest that 
smoking could affect the severity of RA, such as increased radiographic progression of joints 
damage, and the development of rheumatoid factor (RF) [240-242]. However at that time, the 
underlying mechanism was unclear. 
More recently, advances in the understanding of the genetic contribution of RA, and the 
discovery of ACPAs, have shed lights on a potential mechanism. First, it was observed that 
smoking increases the risk of developing anti-CPP antibodies in patients with the 
HLA-DRB1 shared epitope [243, 244]. Interestingly, smoking increases the expression of 
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peptidylarginine deiminase 2 (PAD2) in the lungs, thus increasing protein citrullination [245]. 
Further experiments confirmed the association of smoking, the presence of HLA-DRB1 
shared epitope and ACPAs, suggesting that smoking promotes non-specific citrullination of 
proteins, supporting this lung hypothesis [246]. This is a particularly elegant 
gene-environment association which requires further investigations [247]. However, this 
association could not be replicated in an independent study using different cohorts in North 
America [248]. Some studies also suggest that environmental risk factors such as smoking 
would be more important than genetic predispositions at developing ACPAs, whereas genetic 
predispositions would be more important in determining which ACPA
+
 individuals ultimately 
develop RA [249]. 
2.2.5.2 Sex hormones 
Sexual hormones are also thought to influence arthritis. This is exemplified by the higher 
prevalence in women compared to men. Pregnancy is known to improve symptoms and have 
an impact on the time of disease onset [250-252]. Moreover, epidemiologic studies suggest 
that oral contraceptives could improve the clinical outcome of RA [236, 253-255]. The 
suppressive effect of female sex hormones was also clearly demonstrated in rodent models, 
including in collagen induced arthritis (CIA) [256-258]. Hormone replacement therapy in RA 
patients was shown to have a modest effect on disease progression [259, 260]. However, this 
protective effect is not believed to be specific for RA. Instead, estrogen would have an 
immunosuppressive role which is more general [261, 262]. One study for example suggested 
that it would drive the expansion of Treg [263]. The modest benefit observed in RA is 
however not sufficient to justify the use of hormone replacement therapy considering the 
potential increased risk of cancers [264]. 
2.2.5.3 Bacteria 
As with other autoimmune diseases, infections and peptide mimicry were believed to have a 
significant role in RA [265, 266]. Animal studies suggested that some infectious agents could 
trigger and exacerbate arthritis [267]. Despite major interest in this hypothesis due to 
association studies, causative evidence in human is limited [268]. Hence, this theory was put 
aside for some time. 
More recently, a very interesting mechanism was proposed to link bacteria and RA. Once 
again, the association between ACPAs and RA has been central. Epidemiologic studies 
revealed that RA patients have an increased risk of periodontitis [269]. Periodontitis in adults 
is usually caused by Porphyromonas gingivalis, a bacterium expressing a PAD enzyme 
which could citrullinate host proteins [270]. Antibodies against Porphyromonas gingivalis 
were indeed found to be associated with an increased risk of ACPAs in RA patients [271, 
272]. This is a very elegant theory linking environmental risk factors to a potential 
pathological mechanism. 
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2.2.6 Treatment of RA 
The following section is not meant to cover in details therapeutic strategies for RA. Instead, it 
focuses on major breakthroughs which provided valuable information on the physiopathology 
of RA: clinical efficacy in patients being the ultimate proof-of-concept that a particular 
pathway is important. Understanding pathways implicated in human RA helps to evaluate the 
relevance of various animal models of arthritis. Clinical guidelines would also take into 
consideration potential side effects and costs; however both of these criteria provide little 
insight on the disease itself and are thus not directly relevant to this thesis. The American 
College of Rheumatology published recently their 2015 guidelines [273]. 
2.2.6.1 Glucocorticoids 
The broad anti-inflammatory action of glucocorticoids is effective to control symptoms of 
RA and is still considered a valid temporary addition in initial therapy of moderate to severe 
RA. It can also be used to treat flares. However, it should be used to the lowest possible dose 
and for the shortest possible duration considering the serious side effects associated to 
glucocorticoids. 
2.2.6.2 Disease-modifying antirheumatic drugs (DMARDs) 
As opposed to glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. 
naproxen, indomethacin, diclofenac, ibuprofen) which help to control pain and inflammation 
rapidly but do not affect RA progression, disease-modifying antirheumatic drugs (DMARDs) 
usually act slowly but improve the evolution of RA. Hence, their use is crucial for the long 
term management of RA. DMARDs are now divided in traditional/chemical drugs, and 
biologic drugs. Despite major advances in biological treatments, traditional DMARDs are 
still considered a cornerstone of initial therapy of RA. These drugs include methotrexate, 
sulfasalazine, leflunomide, hydroxychloroquine and gold salts. 
A low dose of methotrexate is the most commonly used DMARD therapy. It is an 
antimetabolite and antifolate drug. It has several effects on the immune system which could 
explain efficacy in RA, including inhibition of T cells and B cells [274, 275]. Table II 
presents biologic DMARDs approved for the treatment of RA. 
2.2.6.3 TNF-α blockers 
The introduction of TNF-α blockers revolutionized treatment of RA almost two decades ago. 
These drugs target the pro-inflammatory cytokine TNF-α and have a very good efficacy with 
a fairly favorable side effects profile. Even nowadays, they are considered the gold standard 
of RA therapy. Among the list of the top 10 global sales for a drug in 2015, 3 are TNF-α 
blockers (Humira, Remicade and Enbrel). TNF-α blockers are usually used in patients after 
unsuccessful initial treatment with traditional DMARD, in particular methotrexate. However, 
this use as second line therapy is mostly explained by the high cost of biologic drugs such as 
TNF-α blockers [276]. Hence, this recommendation is mostly based on pharmacoeconomics 
rather than pharmacotherapy. Upon failure with methotrexate, monotherapy with TNF-α 
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blockers is considered, or combination with methotrexate in partial responders since there is a 
demonstrated benefit of the combination [277]. 
 
Table II - Biologic drugs in the treatment of RA 
Drug Name Brand Description Approval Other indications 
Infliximab Remicade 
Chimeric (mouse/human) 
anti-TNF-α 
1998 
Psoriasis, ulcerative colitis, 
Crohn’s disease 
Etanercept Enbrel 
TNF receptor/Fc fusion 
protein 
1998 Psoriasis 
Anakinra Kineret IL-1R antagonist 2001 - 
Adalimumab Humira Human IgG1 anti-TNF-α 2002 
Psoriasis, ulcerative colitis, 
Crohn’s disease 
Abatacept Orencia CTLA-4/Fc fusion protein 2005 - 
Rituximab Rituxan 
Chimeric (mouse/human) 
anti-CD20 
2006 - 
Certolizumab Cimzia PEGylated Fab’ anti-TNF-α 2008 
Psoriatic arthritis, Crohn’s 
disease 
Golimumab Simponi Human IgG1κ anti-TNF-α 2009 
Psoriatic arthritis, ulcerative 
colitis 
Tocilizumab Actemra Human IgG1 anti-IL-6 2010 - 
Approval: year of approval by the FDA for the treatment of RA 
Other indications: other FDA indications in autoimmune diseases relevant for this thesis 
 
The success of TNF-α blockers has obviously generated a large amount of research, both on 
TNF-α but also other cytokines [278]. Although some patients do not respond to these 
treatments, others experience total remission. This is due to the unique role of TNF-α in the 
inflammatory cascade. In fact, TNF-α blockage is useful for several other autoimmune 
diseases, including psoriasis and Crohn’s disease, demonstrating how central TNF-α is in 
autoimmunity [181, 279]. Not so surprisingly, an increased risk of severe infections and a 
potential association to malignancies are the biggest concerns with these treatments [277, 
280]. The association to malignancies is however still debated [281, 282]. 
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2.2.6.4 CTLA4-Ig 
On T cells, CTLA-4 is an inhibitory receptor binding B7 proteins (CD80 and CD86) of APC. 
Abatacept is a fusion protein composed of the extracellular domain of CTLA-4 and the Fc 
region of IgG1. It acts by binding B7 co-stimulatory molecules on APC, thus preventing 
interaction between B7 and CD28, and therefore T cells activation [283]. It is indicated for 
the treatment of RA refractory to TNF-α blockers [284]. Some data suggest favorable 
comparison to TNF-α blockers, however the large amount of safety information with TNF-α 
blockers along with extensive clinical experience help them maintain their status as a first 
choice within biologic DMARDs [285]. It is interesting to note that blockage of CTLA-4 is 
currently used in cancer immunotherapy to increase T cells response towards malignant cells 
[97]. 
2.2.6.5 Anti-IL-6R 
Tocilizumab, a monoclonal antibody against IL-6R, is also approved for the treatment of RA 
in combination with methotrexate [286]. The development of anti-IL-6R therapy originates 
from the observation that IL-6 is overexpressed in RA [287, 288]. The biological function of 
IL-6 was fairly difficult to understand since it is produced by a wide variety of cells and also 
exerts its effects in various cell types [289]. It is now clear that it is associated to the Th17 
pathway [290, 291]. Tocilizumab was shown to improve clinical outcome in patients with 
poor response to TNF-α blockers [289]. Similarly to TNF-α, IL-6 was associated to a variety 
of autoimmune diseases in animal models, suggesting a central and non-redundant role in 
chronic inflammation [292, 293].  
2.2.6.6 IL-1RA 
Anakinra is a recombinant IL-1 receptor antagonist (IL-1RA) approved in RA. It acts by 
inhibiting the action of IL-1 by preventing its binding to the IL-1R. Secreted by cells of the 
innate immunity, IL-1 has pro-inflammatory properties [294]. Anakinra improves clinical 
outcome in patients receiving methotrexate [295]. This treatment generated a lot of interest 
when it was found to block bone resorption [296, 297]. However, although direct comparison 
are not available, meta-analyses suggest that Anakinra is less effective than TNF-α blockers, 
making this treatment less appealing to clinicians [298, 299].  
2.2.6.7 Anti-CD20 
Rituximab is a monoclonal antibody recognizing CD20, a protein expressed by B cells. It acts 
by depleting B cells which are responsible for humoral response and are also potent APC. 
Rituximab was demonstrated to improve clinical outcome in patients receiving methotrexate, 
including patients refractory to TNF-α blockers [300, 301]. Although it is officially indicated 
for the treatment of RA, the main indication of rituximab is in B cell malignancies [302, 303]. 
B cells depletion has also been investigated for other autoimmune diseases including multiple 
sclerosis and systemic lupus erythematosus [304-306]. 
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2.3 ANIMAL MODELS OF ARTHRITIS 
The complex interplay between genetic and environmental factors in RA makes mechanistic 
studies in human challenging. Several rodent models that mimic various aspects of human 
RA have been developed in order to dissect the pathophysiological mechanisms and evaluate 
novel therapeutic targets [307, 308]. Mice models are particularly useful for early 
investigations to complement in vitro experiments due to the available technology in terms of 
genetic manipulations, as well as their relatively low cost and short gestation period. 
The most commonly used model of arthritis is collagen induced arthritis (CIA), a model 
based on the induction of arthritis by immunization with the joint-specific protein collagen 
type II (CII) and an adjuvant, typically complete freund's adjuvant [309]. Other common 
models include collagen antibody-induced arthritis (CAIA) and adjuvant-induced models 
such as pristane induced arthritis (PIA) in rats [310]. In addition to these inducible models, 
other models are based on genetic modifications that increase susceptibility for arthritis, 
among which the SKG model that shares several interesting characteristics with human RA. 
2.3.1 Collagen induced arthritis (CIA) 
CIA is the gold standard among animal models of arthritis [311, 312]. Studies using CIA in 
mice have allowed the identification of several disease promoting polymorphisms. Similarly 
to RA, MHC haplotype is a major genetic factor in CIA. As mentioned above, the model in 
mice relies on immunization with CII, usually from heterologous origin. Proper presentation 
of the T cell epitope by CII-permissive MHC (e.g. H2-A
q
 and H2-A
r
) is essential to confer 
susceptibility [309, 313]. In agreement with this finding, αβT cells, but not γδ T cells, were 
found to be essential in CIA [314]. 
The immunodominant T epitope in mice expressing H2-A
q
 is the galactosylated CII260-270 
peptide [315]. Post-translational galactosylation of the K264 amino acid in the cartilage is 
thought to be a critical step in CIA [316, 317]. This peripheral modification of CII could 
explain why T cells reactive to this modified peptide are not negatively selected in the thymus 
since it appears not to be presented by mTEC. This is an elegant explanation to the break of 
central tolerance of T cells. It is also particularly relevant to human RA due to the parallels 
with peripheral citrullination of proteins. 
The break of T cells tolerance ultimately leads to the production of high levels of anti-CII 
antibodies in sera [318]. Unlike with T cells, B cells (and antibodies) are highly cross-reactive 
to self-CII due to homology in B cells epitopes. B cell deficient mice do not develop CIA. On 
the other hand, serum transfer, which contains self-reactive antibodies, is pathogenic, 
demonstrating the essential role of this humoral response [319, 320]. This is quite interesting 
when considering the efficacy of rituximab in RA. Extensive characterization of B cells 
epitopes led to the development of another model of arthritis: CAIA (see section 2.3.2 
below). 
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Restrictions in terms of susceptible strains are a significant limitation to the use this model 
since CII-permissive MHC is required. Still, CIA has proven to be very useful in drug 
development. For example, the importance of the IL-6 pathway was demonstrated in CIA 
using IL-6
-/-
 mice [321]. TNF-α blockage and anti-IL-1 were also shown to be effective in 
CIA [322, 323]. Finally, blockage of B7 co-stimulatory molecules using CTLA4-Ig was also 
effective in CIA [324]. 
2.3.2 Collagen antibody-induced arthritis (CAIA) 
CAIA is a mouse model in which arthritis is induced using a cocktail of CII-specific 
monoclonal antibodies followed by innate stimulation (e.g. LPS injection). This model relies 
on the understanding of CII epitopes recognized in CIA, and demonstrates directly the 
pathogenicity of anti-CII antibodies at high concentrations [325, 326].  
Unlike CIA, this model is not MHC-restricted. In fact, there is a strong non-MHC genetic 
contribution to disease susceptibility. Both B cells and T cells are not essential. On the other 
hand, FcγRs are very important in modulating disease susceptibility [327]. In terms of 
cellular effectors, neutrophils depletion prevents disease development, whereas C5-deficient 
mice are partly protected, both demonstrating a crucial role of neutrophils [328]. 
Macrophages are also essential in CAIA [329]. A mice study using C3
-/-
 and factor B (FB)
-/-
 
strains further revealed an implication of both the classical and alternative activation of the 
complement system [330]. Finally, both IL-1 and TNF-α were demonstrated to be implicated 
in the pathogenesis of CAIA using knockout mice, which is in accordance to RA [331]. 
However, IL6
-/-
 mice had normal CAIA. 
The CAIA model is mostly useful to study the effector phase of joints inflammation. It can be 
advantageous in drug screening due to its quick onset, and also its relative ease of use 
regarding susceptible strains (no MHC restriction) [332].  
2.3.3 K/BxN serum transfer 
K/BxN mice express the TCR transgene KRN that was designed to recognize the bovine 
ribonuclease peptide (RNase42-56) on MHC I-A
k
 [333]. Unexpectedly, this TCR transgene 
recognizes a peptide from the ubiquitous glucose-6-phosphate isomerase (GPI) on the MHC 
II-A
g7
 derived from the NOD strain. This reactivity to GPI makes these mice susceptible to 
spontaneous arthritis. Although the model is T cells and B cells dependent, serum transfer 
from these mice is sufficient to induce arthritis in lymphocytes deficient recipients. 
Interestingly, immunization with GPI can also induce arthritis, a model implicating the 
IL-6/IL-17 pathway [334, 335]. 
Similarly to CAIA, TNF-α and IL-1 were found to contribute to joints inflammation upon 
antibodies transfer in knockout mice, whereas IL-6 did not [331]. Moreover, neutrophils 
depletion protected mice against K/BxN serum transfer, potentially by preventing the 
production of LTB4 from neutrophils [336, 337]. Finally, FcγRs (in particular FcγRIII) and 
complement activation are important for the pathogenicity of sera [338]. 
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2.3.4 Pristane induced arthritis (PIA) 
An interesting and intriguing model of arthritis is the pristane-oil induced arthritis PIA in rats 
[339]. Both MHC and non-MHC genes influence this disease. The exact pathogenesis, 
including the disease specific antigens, remains to be fully understood. Nevertheless, the 
disease inducer (pristane) is a well-defined molecule, which after injection causes a chronic 
relapsing arthritis in susceptible strains with a prevalence of virtually 100% [340]. Studies 
using irradiation followed by repopulation revealed that CD4
+
 T cells are needed for disease 
development, whereas B cells and CD8
+
 T cells are not [341]. T cells activated in vivo can 
induce PIA in recipient rats upon transfer, confirming the central role of pathogenic T cells in 
this model [342].  
2.3.5 The SKG model 
The SKG model was originally described by Sakaguchi et al. in 2003 [343]. A spontaneous 
point mutation which occurred in a BALB/c colony made these so-called SKG mice 
susceptible to spontaneous chronic arthritis when kept in conventional animal facilities. This 
non-synonymous mutation in ZAP70 (W163C) reduces TCR signaling and alters thymic 
selection, leading to leakage of arthritogenic CD4
+
 T cells in the periphery of homozygote 
mutants [344]. Figure 9 illustrates the shift of T cells repertoire towards self-reactivity in 
SKG mice. This intrinsic defect in lymphoid progenitors was shown to still be pathogenic 
after transfer, even in mice of a different genetic background [343, 345]. Studies have 
revealed that the precise degree of reduction in TCR signaling is critical to arthritis 
susceptibility [344, 346]. In this thesis, we investigated the establishment of the SKG model 
in black strains with the MHC H2-A
q
 haplotype (Paper II).  
2.3.5.1 Self-antigens in SKG mice 
The root of autoimmunity in SKG mice is clearly demonstrated to be self-reactive CD4
+
 T 
cells that escape central tolerance mechanisms. However, it remains unclear what are the key 
self-antigens triggering T cells activation. Early publications have identified several 
self-antigens targeted by antibodies, such as CII and heat shock protein-70 (HSP-70). Unlike 
with the K/BxN model, transferring sera does not confer arthritis, suggesting that these 
antigens might not necessarily be driving joints inflammation [343]. Due to the importance of 
CII reactivity in arthritis, we conducted a detailed investigation on CII as a potential self-
antigen in SKG mice (Paper III).  
In arthritic SKG mice, an increased frequency of T cells expressing TCR Vβ2 and TCR 
Vβ8.2 was observed, suggesting their implication in the disease development [347]. In an 
attempt to better comprehend this self-reactivity, two T cell clones were created from joint 
infiltrating T cells [348]. Both clones could lyse syngeneic synovial cells. However, one 
clone could also specifically lyse other MHC-matched cells, suggesting reactivity against a 
ubiquitous antigen. Interestingly, the two clones could induce independently arthritis and 
pneumonitis when transferred in nude recipients. More recently, Ito et al. identified self-
reactivity against the ubiquitously expressed 60S ribosomal protein L23a (RPL23A) [349]. 
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This finding is particularly interesting because self-reactivity against this protein is also found 
in T cells and sera of RA patients [349]. These results reinforce the notion that self-reactivity 
observed in SKG mice is relevant to human RA. However, identification of a ubiquitous 
antigen raises questions as to why joints are particularly affected in SKG mice.  
 
 
Figure 9 – Defective central tolerance in SKG mice due to deficient TCR 
signaling  
Thresholds of intracellular TCR signaling strength determine the faith of thymocytes 
during T cells positive and negative selections. In wild-type animals, the selections will 
result in the removal of non-functional and self-reactive T cells. In SKG mice however, 
reduced TCR signaling alters the equivalent TCR affinity towards MHC-peptide 
complex needed for T cells to pass selections, leading to a general shift of repertoire 
towards self-reactivity. 
 
2.3.5.2 A model sensitive to the environment 
Spontaneous arthritis onset is not observed in SKG mice kept in specific pathogen free 
facilities (SPF), suggesting that arthritis in this model is due to a combination of genetic and 
environmental factors, something mimicking human RA [350]. Despite the presence of 
arthritogenic CD4
+
 T cells in the periphery of SKG mice kept in SPF, activation of innate 
immunity with specific adjuvant is first needed to trigger chronic arthritis. Studies are now 
primarily conducted in SPF facilities with innate triggering because it allows a better control 
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over experimental factors such as microflora and time of onset, thus increasing 
reproducibility between experiments and different research centers. 
Screening of adjuvants revealed that the β-glucan zymosan A and poly(I:C), but not LPS, 
ConA, pristane, pertussis toxin, cyclophosphamide, anti-CD40 and rat-IgG, could induce 
significant arthritis with an incidence approaching 100% [351]. It was later found that other 
extracts from Candida albican, such as mannan and curdlan, were also efficient [352-354]. 
Paper I focuses on innate immunity activation by mannan in non-SKG mice. 
2.3.5.3 Sex hormones 
Another environmental factor well known to influence human RA is sex hormones. 
Epidemiological studies clearly demonstrate a higher prevalence in women, which could be 
explained by the effects of estrogens, androgens and progesterone on inflammation [206, 
355]. Early studies revealed a bias towards higher severity in female SKG mice, similarly to 
human RA, prompting some groups to further investigate sex hormones in SKG arthritis 
[343]. Sex does not only influence joints inflammation, but also periocular inflammation 
[356]. Testosterone is protective in SKG arthritis [357]. Pregnancy improves arthritis 
severity, similarly to remission observed in human [358, 359]. A different group also 
demonstrated that ovariectomy enhanced SKG arthritis, whereas 17β-estradiol treatment was 
slightly protective [360].  
2.3.5.4 Effects of joint inflammation on bones 
Several groups used the SKG model to study the effects of chronic inflammation on bones. 
Chronic inflammation in SKG mice led to reduced mechanical strength of bones, and 
disturbed collagen network organization, most likely due to increased bone turnover [361, 
362]. Increased bone resorption was associated to increased number of osteoclasts on bone 
surfaces [363]. Further investigation identified the presence in the bone of osteoclast 
precursors derived from bone marrow myeloid population [364]. These osteoclast precursors 
have osteoclastic activity, and share features of both M1 and M2 macrophages. Surprisingly, 
they have suppressive effects on T cells, and can decrease the severity of arthritis in a SKG 
adoptive transfer model. Due to the effect of SKG arthritis on bones, the SKG model was also 
used to evaluate the impact of therapy on bones, and also the effect of therapy specifically 
against bone resorption [365, 366]. 
2.3.5.5 Other sites of inflammation 
Although joints are the primary sites of inflammation, various groups have also described 
other forms of autoimmunity accompanying arthritis in SKG mice. This is not surprising 
considering that the mechanism leading to autoimmunity is defective central tolerance of T 
cells. Hence unlike in CIA for example, it is not specifically targeting joints. However what is 
surprising is that the adjuvant used, and potentially the microflora, alters the organs affected 
by autoimmunity. For example, it was found that curdlan, but not mannan, also induces 
uveitis and ileitis resembling Crohn’s disease which seems to be caused by changes in the gut 
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microflora [354, 367, 368]. A different group recently described both periocular and lung 
inflammations with both curdlan and zymosan A, but not uveitis [356]. Lung inflammation 
itself had already been described by various other groups [348, 369, 370]. Finally, skin 
infiltrates were observed in arthritic SKG mice kept in conventional animal facility, however 
mannan itself was also found to cause dermatitis even in non-SKG mice, potentially 
confounding any further investigations [343, 371]. These disparate autoimmune profiles are 
not necessarily contradictory, but only reinforce the sensitivity of this model to environmental 
factors such as microflora. Nevertheless, joints seem to be particularly susceptible to 
inflammation since no group reported an absence of arthritis. 
2.3.5.6 Cytokines network in SKG arthritis 
There is major interest in understanding the cytokines network associated with arthritis in 
SKG mice, partly because of the therapeutic importance of cytokines blockage in human RA, 
such as TNF-α blockers [372, 373]. It was established early that IL-6, IL-1 and TNF-α were 
overexpressed in arthritic synovial tissue, and that their absence in knockout mice greatly 
reduced, or even abolished, arthritis onset in SKG mice, whereas the lack of IL-10 leads to 
increased disease severity [374]. The increase in IL-6 levels was also observed in zymosan A 
treated mice [375]. However, it was somewhat surprising that neither IFN-γ nor IL-4 
influenced arthritis in SKG mice, which did not fit with the reigning Th1/Th2 paradigm at 
that time [374].  
Understanding the role of IL-17 in arthritic SKG mice was a major breakthrough in 
understanding the underlying cytokines network operating [376]. Similarly to human RA, the 
major source of IL-17 in synovium is αβT cells in the SKG model, and not γδT cells like it is 
in CIA [377]. In fact, γδT cells in SKG mice are deficient in terms of IL-17 production due to 
the mutation in ZAP70 [378]. These Th17 cells express CCR6 and are recruited in joints by 
CCL20 produced by synoviocytes [379].  
Subsequent studies revealed that exposure to zymosan A leads to the secretion of GM-CSF, 
which in turn activates macrophages production of IL-1β and IL-6 [369]. The resulting 
cytokines microenvironment favors Th17 differentiation and further production of GM-CSF 
and IL-17. The activation of macrophages and subsequent Th17 differentiation is dependent 
upon complement activation of C5a [352]. As mentioned by the authors, C5a, IL-17 and 
GM-CSF are all potent enhancers of granulopoiesis and will cause the recruitment and 
accumulation of neutrophils in inflamed tissues. The lack of ROS burst due to defective 
NOX2 complex in SKG.Ncf1
m1j/m1j
 mice was also shown to increase accumulation of 
neutrophils in inflamed joints (Paper IV). 
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Figure 10 – Key mediators of arthritis in SKG mice after zymosan A or 
mannan injection  
Defective central tolerance in SKG mice causes the leakage of self-reactive T cells in 
the periphery. Activation and recruitment of these T cells are however necessary to 
induce joints inflammation. A single injection of zymosan A or mannan leads to 
macrophages activation via complement C5a and various PRRs. Production of IL-1β 
and IL-6 lead to T cells activation and differentiation into Th17. Local secretion in the 
joints by synoviocytes of the chemokine CCL20 recruits Th17 expressing CCR6 in the 
joints where they secrete IL-17 and GM-CSF. Both cytokines help to the recruitment 
and activation of neutrophils and monocytes while also inducing granulopoiesis. 
Secreted enzymes from these cells, and from osteoclasts, slowly erode joints. 
  
  33 
Neutralization of either GM-CSF or IL-6, but not IL-17, greatly reduced lungs inflammation 
[369]. Joints inflammation itself was only slightly reduced by antibody neutralization of 
IL-17, however a different group later demonstrated that in SKG.IL-17
-/-
, there is a clear 
reduction in joints inflammation and ileitis [368]. The same group also highlighted the 
importance of IL-23, also supporting the implication of Th17. This distinction between 
depletion with antibodies and knockout technology could be explained by a potentially 
incomplete depletion of IL-17 locally in inflamed tissues, supporting a local role of this 
cytokine in SKG arthritis. 
Altogether, the cytokines network identified in SKG mice is relevant to human RA, as 
demonstrated by the similarities between these cytokines and the pathways targeted by 
biologic drugs in RA (e.g. TNF-α, IL-6, IL-1). In fact, except for rituximab which targets B 
cells, all biologic DMARDs approved in RA target pathways implicated in SKG arthritis 
[380]. Figure 10 proposes a cytokines network based on various publications. 
 
2.3.5.7 SKG mice in drug discovery 
Animal models are usually used for two distinctive, yet critical, reasons. The first is to dissect 
mechanisms of arthritis and get valuable information on the biological problem. The second 
is to investigate novel therapeutic interventions. Animal experiments are ideal to evaluate 
novel interventions in highly controlled conditions compared to clinical studies, and allow 
evaluation of therapeutic approaches using genetic modifications before having to develop a 
molecule. Highly controlled conditions reduce variability, and thus reduce the number of 
subjects needed to detect statistically significant effects. Moreover, knockout mice represent 
absolute suppression of a particular pathway; hence they give an indication of the maximal 
efficacy possible to reach because due to pharmacological limitations, a drug is likely to not 
fully inhibit a certain pathway. 
Altogether, animal experimentations are an essential step between in vitro experiments and 
clinical trials as it allows a complex in vivo proof-of-mechanism while minimizing the risk 
for human subjects. However, a critical question to address is how good an animal model is at 
predicting safety and efficacy in human due to interspecies discrepancies, and the inherent 
shortcomings of modeling a disease. 
The relevance of an animal model is often measured by its ability to predict efficacy of 
treatments in human. There exists however a bias in this analysis, especially with older 
models such as CIA, because only drugs effective in these models will have been further 
investigated in the first place. This bias is absent in newer models, such as the SKG mice, 
since most drugs were discovered before the model. However, being newer, these models are 
not as well understood which could also be problematic. A prudent approach to circumvent 
these issues is to use a combination of independent models where different immunological 
pathways are involved. For instance, using both CAIA and K/BxN sera transfer, or CIA and 
CAIA, provides little additional information considering their similarities. On the other hand, 
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the addition of the SKG model to CIA helps at eliminating potential bias due to immunization 
(e.g. directing the adaptive immune response to a specific antigen), while still addressing the 
production of pathogenic self-reactive antibodies. 
Due to the high incidence and the rapid onset of arthritis in SKG mice, it presents many 
practical advantages to study novel therapies to treat RA. The mechanisms leading to arthritis 
and several features of arthritis in SKG mice are very relevant to human RA. Limited 
knowledge and expertise in the SKG model, the need for homozygote mutants and 
restrictions in available strains might have slowed the implantation of the SKG model in 
arthritis research. Nevertheless, several studies have already used this model, particularly in 
the past 5 years, to evaluate either novel or existing treatments [380-390]. In fact, tofacitinib – 
the first Janus kinase (JAK) inhibitor approved for RA and the most recently FDA approved 
innovative drug (February 2016) – was also tested in SKG mice prior to its launch [380]. It is 
now reasonable to think that this increased use of the SKG model will continue in the next 
few years. It will be interesting to follow the outcome of these novel therapeutic approaches 
to see the predictive value of the SKG model. A systemic evaluation of existing drugs in 
SKG mice would also provide valuable information regarding its predictive value. 
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3 PRESENT STUDY 
This thesis includes 4 manuscripts, all of which dealing with autoimmunity in mice. The 
focus is on chronic arthritis in SKG mice induced by mannan. Paper I describes the innate 
immunological events following mannan injection in non-SKG mice. Paper II, III and IV 
then use this innate stimulation as a trigger to chronic Th17-driven arthritis in SKG mice. 
Paper II describes the similar autoimmune profile observed in SKG mice on the B6.Q and 
B10.Q genetic backgrounds. Paper III studies the role of CII as a potential self-antigen in 
SKG arthritis. And finally, paper IV investigates the regulatory role of ROS in autoimmunity. 
3.1 PAPER I: MANNAN INDUCES ROS-REGULATED, IL-17A–DEPENDENT 
PSORIASIS ARTHRITIS-LIKE DISEASE IN MICE 
Mannan is a polysaccharide extracted from the wall membrane of yeast. It is believed to 
activate innate immunity through various PRR, including dectin-2 receptors [29]. This 
publication describes how mice exposed to a high dose of mannan i.p. experience transient 
joints and skin inflammations. This finding is interesting considering that a combination of 
joints and skin inflammation mimics psoriasis and psoriatic arthritis, and thus represents a 
new model of this disease.  
This publication highlights the importance of ROS as regulators of inflammation since skin 
and joints inflammation in Ncf1
m1j/m1j
 mice lacking NOX2-dependent ROS burst is greatly 
enhanced. Neither B cells nor αβT cells were essential; however macrophages played a 
significant role. Further investigation revealed that IL-17A and neutrophils were critical to 
both skin and joints inflammations. Considering the absolute protection in RAG
-/-
 (data not 
shown), and that γδT cells, from both the peritoneal cavity and the skin, were found to 
produce high amounts of IL-17A upon in vivo stimulation, we postulate that these cells were 
likely implicated in the pathogenesis of this novel animal model of psoriasis. However, direct 
causality, for instance by γδT cells depletion or knockout mice, was not demonstrated. 
Understanding the inflammatory cascade following mannan injection is critical since it leads 
to the activation of pathogenic SKG T cells in SKG mutant mice, and the subsequent chronic 
arthritis. In non-SKG mice, such as in this publication, the inflammation self-resorbs due to 
the lack of pathogenic SKG T cells. It is worth noting however that in SKG mice, γδT cells 
are severely deficient in terms of IL-17A production and are therefore unlikely to be a 
significant acute source of IL-17A upon mannan stimulation (data in supplementary figures 
of paper II). Hence, the acute source of IL-17A remains unknown in SKG mice. 
3.2 PAPER II: THE SKG MUTATION IN ZAP-70 ALSO CONFERS ARTHRITIS 
SUSCEPTIBILITY IN C57 BLACK MOUSE STRAINS 
The SKG model was originally discovered in a BALB/c colony [343]. Similarly to the 
PTPN22 mutation, the ZAP70 mutation leads to reduction in TCR signaling and is unspecific 
in terms of autoimmunity. In SKG.BALB/c mice, it led to joints inflammation; however it is 
unclear why joints in particular are affected, similarly to human RA. The effect in terms of 
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autoimmune profile of this point mutation in a different genetic background or a different 
MHC haplotype was thus unknown. Before this study, no other strains had been used to study 
SKG arthritis. Having the SKG model available in black strains, in particular the B6 strain, 
has significant importance considering the wide use of this background for genetically 
modified strains. Moreover, most arthritis research is conducted in mice bearing the MHC 
H2-A
q
 haplotype due to their susceptibility to CIA.  
Therefore, in this publication, we describe the backcrossing over more than 10 generations of 
the SKG mutation on the B6.Q and B10.Q genetic backgrounds. Mice retained impaired TCR 
signaling as demonstrated by reduced calcium influx and reduced proliferation following 
anti-CD3/anti-CD28 stimulation. Similarly to SKG.BALB/c, this reduced signaling had a 
profound effect on thymic selection, reducing output from both DN3 to DN4, and more 
significantly from DP to SP. Arthritogenic T cells hence escaped thymic selection, leading to 
susceptibility to chronic T cell driven arthritis upon activation of the innate immune system 
with mannan. Imputability of T cells was demonstrated using adoptive transfer. The SKG 
mutation led to aberrant T cells activation with a strong bias towards Th17, and production of 
self-reactive antibody against CII. 
Results in this manuscript should hopefully help to spread the use of the SKG model by other 
research groups. These results were also the foundation of the two other manuscripts in this 
thesis since it allowed complex crossing with the large collection of transgenic strains on the 
B10.Q genetic background used in our research group. 
3.3 PAPER III: T CELL SPECIFICITY AGAINST GALACTOSYLATED CII 
ENHANCES COLLAGEN INDUCED ARTHRITIS IN SKG MICE BUT DOES 
NOT AFFECT ADJUVANT INDUCED ARTHRITIS 
As demonstrated by research on ACPAs in RA, biomarkers research in arthritis is essential to 
understand the disease. Moreover, understanding the role of specific self-antigens is essential 
in the development of targeted therapeutic interventions such as vaccination. The role of CII 
as a potential self-antigen, and of anti-CII antibodies, are thus of significant importance. In 
human, anti-CII antibodies are found in a subset of patients with rapidly progressive RA 
[391, 392]. Moreover, in animal models of arthritis, high reactivity against CII is known to be 
pathogenic, as demonstrated by CIA and CAIA [309, 325, 326]. However, the contribution of 
low self-reactivity against CII in the development of arthritis still remains unknown. 
The SKG model represents a unique opportunity to address this question considering that 
these mice develop spontaneously anti-CII antibodies after mannan injection, despite the lack 
of immunization with CII. To fully address the role of CII reactivity in this model, SKG mice 
were first crossed with CII-permissive MHC H2-A
q
. Then, they were crossed with CII-
specific βTCR (Vβ12) and αβTCR (HCQ.3) transgenic strains to enhance CII reactivity. 
Finally, T cells repertoire was fixed to react solely against CII by fixing the repertoire to 
HCQ.3 using RAG
-/-
. 
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Increased T cells reactivity against CII and expression of MHC H2-A
q
 made SKG mice 
susceptible to CIA. An expansion of CII-specific T cells is observed after CII immunization 
in SKG.Vβ12, whereas a large pool of CII-specific T cells is already presents even in naïve 
SKG.HCQ.3 mice. Despite these observations, both SKG.Vβ12 and SKG.HCQ.3 are equally 
susceptible to arthritis following mannan injection compared to SKG mice, suggesting that T 
cells reactivity against CII has no effect in this model. Furthermore, fixing T cells repertoire 
to CII reactivity abolishes mannan induced arthritis, supporting that reactivity against other 
antigens is what drives chronic arthritis in SKG mice. 
Altogether, this publication highlights the complementarity of CIA and SKG arthritis. Indeed, 
CIA-promoting transgenes such as Vβ12 and HCQ.3 had no effect in SKG mice. Such 
distinction is interesting since it demonstrates that findings from CIA could greatly benefit 
from an independent evaluation in SKG mice. Finally, since increasing CII reactivity did not 
alter arthritis susceptibility in SKG mice following mannan injection, it suggests that the 
observed anti-CII antibodies are not a crucial part of this disease model, raising questions 
regarding their implication in human RA. 
3.4 PAPER IV: ROS REGULATE INNATE BUT NOT ADAPTIVE 
INFLAMMATION IN ZAP70 MUTATED SKG ARTHRITIC MICE 
The antimicrobial role of ROS produced by neutrophils and macrophages is essential for host 
defense [393]. In human, defects in NOX2 lead to a rare immunodeficiency named chronic 
granulomatous disease (CGD) characterized by apparition of granuloma in various organs 
due to the incapacity of phagocytes to kill bacteria [394]. In chronic inflammation however, 
such as in arthritis, the role of ROS is traditionally believed to be deleterious because it is 
thought that prolonged tissue exposure to ROS can cause collateral tissue damage. 
This pathogenic role of ROS in arthritis was seriously challenged when genetic studies 
revealed that an arthritis promoting polymorphism in rats was a mutation within Ncf1 leading 
to reduction in ROS burst by phagocytes [395]. This disease enhancement by deficient ROS 
burst was confirmed in Ncf1
m1j/m1j
 and GP91
-/-
 mice, in which susceptibility to CIA was 
greatly enhanced despite the abolition of NOX2 activity [396, 397]. Interestingly, CGD 
patients were later found to have an increased risk of autoimmune diseases compared to the 
general population [398]. 
Despite this clear demonstration that a lack of ROS from phagocytes promotes arthritis, the 
mechanism leading to down-regulation of the immune response remained poorly understood. 
A previous study suggested that reduction of thiols on the surface of T cells in ROS-deficient 
rodents increase activation and arthritogenicity of T cells [399]. Furthermore, 
ROS-deficiency in Ncf1
m1j/m1j
 mice led to break in T cells tolerance towards endogenous CII, 
however it was unclear if this was a central or peripheral effect [400]. Other studies suggested 
that ROS would exert their effect through innate immunity. For instance, activation of DC 
with M. tuberculosis leads to higher production of IL-6 and TFG-β, and a subsequent bias 
towards Th17 and increased CIA susceptibility in ROS deficient mice [401]. Finally, 
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macrophage-derived ROS were found to be protective in CIA, and also in B cell and T cell 
independent mannan-induced psoriatic arthritis [371, 402]. Altogether, these results 
demonstrate the need to further investigate the immunoregulation mechanisms of ROS. 
The uniqueness of the SKG model gave us the perfect setting to revisit several hypotheses 
generated with previous arthritis models. In vivo imaging revealed a high burst of ROS 
production in arthritic joints of SKG mice, followed by steady, yet abnormally elevated, ROS 
levels in inflamed joints. To characterize the effect of ROS in SKG arthritis, SKG.B10.Q 
mice were crossed with Ncf1
m1j/m1j 
mice to generate ROS deficient SKG.Ncf1
 m1j/m1j 
mice. As 
observed in CIA, ROS deficiency greatly enhances arthritis susceptibility of SKG mice. This 
increase in arthritis severity is associated to elevated concentrations of anti-CII antibodies in 
the blood; however transfer experiments demonstrated that the sera were not pathogenic. 
Regarding T cells, no difference were observed regarding thymic selection or T cells activity 
in the periphery in absence of ROS. Adoptive transfer of peripheral T cells revealed a crucial 
role of peripheral ROS. Using transgenic mice expressing functional Ncf1 under the hCD68 
promoter, it was found that macrophage-derived ROS can regulate arthritis. Altogether, this 
publication highlights the role of macrophage-derived ROS in regulating T cell driven 
autoimmunity independently of adaptive immune response, which has therapeutic 
implications. 
3.5 PERSPECTIVES 
Paper I introduces a new model of psoriatic arthritis and identifies a potential disease 
mechanism. Although the role of IL-17 was clearly demonstrated, and despite that γδT cells 
seem to be a potent source of it after mannan stimulation in vivo, it remains unproven that 
they are key contributors in this disease model. The absolute abolition of disease 
susceptibility in RAG
-/-
 supports this idea. However, SKG mice are equally susceptible to 
mannan induced psoriasis-like lesions, yet their γδT cells are severely deficient in terms of 
IL-17 production. This suggests that at least in SKG mice, another major source of acute 
IL-17 production exists. The use of knockout strains and depleting antibodies could provide 
the answer to this question. 
Considering that it is a new model, it would be interesting to study the response to various 
treatments used in psoriasis and psoriatic arthritis. Indeed, this model presents many practical 
advantages in drug screening (e.g. fast onset, high incidence), however the relevance to 
human is still unknown. On the other hand, the very short duration of this model might be 
problematic. Although the lack of a role for αβT cells in this model raises questions regarding 
the relevance of this model, downstream and effector mechanisms (e.g. IL-17 and 
neutrophils) might still mimic the human pathology. Demonstrating a good predictive value 
of this model in hence the required next step to make the model attractive to researchers.  
To our knowledge, paper II is the first report that the SKG model can be used on a different 
genetic background than BALB/c, including also a different MHC haplotype. The method 
used was insufficient to exclude an effect of MHC haplotypes on disease severity. Systemic 
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screening of various MHC, along with backcrossing of the SKG mutation to other mice 
strains could represent an interesting tool to detect arthritis promoting genes. A similar 
method with other animal models was used to identify several risk loci (e.g. polymorphism in 
Ncf1). In the meanwhile, due to its uniqueness, the SKG.B10.Q mice model can be used to 
further investigate previously identified disease promoting polymorphisms. This thesis 
presents two projects which focused on previously identified factors enhancing CIA: the CII 
reactivity of T cells, and the lack of NOX2-derived ROS burst. 
Considering the results of paper III, it does not seem appropriate to further study the role of 
CII in SKG mice. Instead, future investigations should focus on identifying other antigens 
driving chronic arthritis in SKG mice. The fact that the model could be transferred to a new 
MHC suggests either that several redundant antigens are implicated, or that the self-antigen 
binds both MHC molecules. Further crosses to new MHC molecules could help to investigate 
this question and thus help to identify pathogenic self-antigens. Regarding the role of CII 
reactivity in human RA, although this study raises questions, it is insufficient by itself to draw 
any firm conclusions. 
Finally, regarding the immunoregulation of arthritis by ROS described in paper IV, the 
ultimate goal of this large endeavor is the development of a drug using this anti-inflammatory 
function of macrophage-derived ROS to treat RA. However, several key questions remain 
unanswered. An urgent issue is to exclude the possibility that ROS either directly or 
indirectly induce pain. Another important issue is to demonstrate that the observed 
suppressive effect of ROS can be further increased with supra-physiologic ROS production. 
In fact, we were only able to demonstrate that the absolute lack of ROS burst from 
phagocytes enhances arthritis, and that restoring ROS production in macrophages restores 
normal arthritis susceptibility. 
Moreover, it would be interesting to identify the precise oxidative molecules suppressing 
inflammation. This would help in the development of therapeutic approaches to alter the 
redox balance. Instead of NOX-2 inducers, directing this balance towards specific oxidative 
molecules by inhibiting key conversation enzymes might be more appropriate. Finally, 
although macrophage-derived ROS from NOX2 were protective in arthritis, it does not 
exclude the possibility that other cellular sources of ROS (e.g. neutrophils) or that ROS from 
other NOX complexes could have a similar role. 
The mechanism of ROS-induced immunosuppression is still not fully understood, but two 
avenues are particularly relevant to investigate at this point. It appears that the underlying 
mechanism is fairly broad since many disease models are affected by ROS deficiency: from 
innate model like mannan induced psoriasis, to B cell and T cell dependent model such as 
CIA. It could also be that ROS operates by various mechanisms in different models, which 
would greatly complicate further investigations.  
The first mechanism to investigate is the local survival of cells, in particular effector cells 
such as neutrophils, in inflamed tissues. Excess of ROS is known to induce apoptosis [403, 
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404]. This could represent a physiological negative feedback mechanism to limit ongoing 
tissue inflammation, and aberrant ROS deficiency could disrupt it. 
The other mechanism to investigate is the polarization of macrophages. Local ROS levels 
could influence differentiation of macrophages from M1 to M2 phenotype. Again, this 
mechanism would be logical from a physiological perspective since a shift to tissue repairing 
M2 phenotype following tissue inflammation would help the organism recover from 
infections. ROS were shown to be critical in alternative differentiation of macrophages and 
generation of tumor-associated macrophages, which strongly support a similar role in 
autoimmunity [405]. Hence, the various mice strains used in the lab to study the role of ROS 
in autoimmunity could also be very useful in cancer research. 
3.6 CONCLUDING REMARK 
In conclusion, the SKG model has received growing interest from the arthritis research 
community ever since its original publication in 2003. Features relevant to human RA, along 
with a unique pathogenesis, make this model an interesting tool for researchers to study 
biological questions related to arthritis and autoimmunity. The increasing use of the SKG 
model in drug discovery in the past few years should reveal how relevant the model is to 
human RA. Hopefully, the work presented in this thesis should facilitate the use of this model 
by various research groups, as well as contribute to the overall understanding of 
autoimmunity. 
  41 
4 ACKNOWLEDGEMENTS 
It feels as if it was only yesterday that I left Switzerland for Sweden. Still, in these 4 years, a 
lot of things have happened, some good and some bad. I met great people, have worked hard 
and learned a lot about research and myself. Of course, like anyone else, I faced numerous 
challenges over these years, but thanks to the support I received, I am now here today, 
finishing my PhD and about to engage in a new adventure. I would like to take the time to 
acknowledge everyone who has made this possible. 
First, thank you Kajsa for giving this great opportunity. I have grown as scientist over the 
past 4 years, and this is thanks to you. You trusted me and gave me a lot of scientific freedom 
while still always taking the time to discuss with me about my projects. I hope the experience 
was as positive for you as it was for me. My PhD wouldn’t have been the same without the 
advices and knowledge of Rikard, which also created a unique environment for research 
(MIR), providing all the tools, resources and expertise needed for research of the highest 
quality. Also thank you Liselotte for your support and advices when I needed it. Although 
not being directly implicated in my projects, thank you to both Nan and Johan for your 
expertise and your various management responsibilities in the group. 
I would also want to acknowledge all my previous mentors which prepared me for a PhD at 
Karolinska Institutet. Thank you Patrice for introducing me to immunology and arthritis. 
Roxane for a great master opportunity and your constant supports, even nowadays. Also, 
thank you Jean-Christophe for this great opportunity at ETH and your understanding after I 
decided to leave drug delivery. Thank you also to Marc and Bastien for your help and 
support in organic chemistry. 
Thanks also to all my ex-colleagues at ETH for all the good times; I hope we meet again 
soon. It was great to meet again Nancy, and you are most definitely welcome wherever I end 
up. Elisabeth for all these nice conversation and being so good at keeping in touch. Stefan, 
you were an awesome flatmate and I really miss going out with you and Julia. Finally, thank 
you Fabienne for the great times we had together, and for helping me make this big decision, 
find the courage to do it and support me in my decision. 
To all my colleagues at MIR, past and present, which made those years at MIR a unique 
experience – thank you. Erik of course, always in the mood for interesting discussions, and 
who has always been very supportive from the start to the end. We worked a lot together, but 
most importantly, we had great evenings. I’m really happy for you and Nastya. It’s hard to 
think of those evenings without remembering the good times with both Florian and Clara. 
 42 
Mike and Gonzalo for being so original, unique and fun. Thank you Daniëlle for all the good 
times and running toughest Copenhagen with me. 
Thanks Katrin for showing me around when I first arrived in the lab, and for taking care of 
my mice while I was away. Min for your enthusiasm, your great science and your honesty. 
Thanks to you and Lena for our small collaboration about neutrophils. Liesu for always 
smiling, even after long days down at the animal house. Thank you Amit for always being in 
a mood for a joke.  
A general thank you to the Chinese community in the lab for sharing with us so many 
dumplings (Bibo, Dongmei, Naru, Changrong, Lilu, Bingze, Wenhua)! Big thanks to 
Jianghong for all your advices and our work together at setting up in vivo imaging and 
studying L-NAME. Cecilia for the collaborations on CAIA mannan. Anthony for your 
advices on accommodations in Stockholm. Outi for the TN3 mice. Vilma for the help with 
nitrogen tanks. Ulrika for tolerating my eating habits in the office. 
Thank you Angel for all the administrative help over the years. All this animal work was 
possible thanks to great animal care by Carlos the Boss, Kristina and all the other 
technicians over the years. Biborka for your role with the veterinarian and ethical issues: 
you’ve always been helpful and comprehensive. Emma for the great histology. Susanne for 
making the lab a little more functional. I’d like to acknowledge past members too – Susann, 
Bruno, Sabrina, Jonathan, Ingrid, Martina and Ia - for all the wise advices about both 
research and career.  
In 4 years in Sweden (and 5 in Europe), I have met a lot of great people. It is impossible to 
name everyone, I’m really sorry, but of course all you fantastic people from both national 
schools in DDD and NCRSCID. Also, I was fortunate enough to meet wonderful people at 
the FEBS 2013 immunology course in Croatia, SIICA 2015 in Catanzaro, and more recently 
REDOX 2016 in Nebraska. And also at national conferences like Basic to Clinic and KiiM 
retreat. Thank you also to Anna and the whole team at Scandinavian Development Service 
for this great opportunity to learn drug development from the best. 
Although I am excited to start soon with new challenges, leaving Stockholm and my friends 
is quite sad and I will miss you all. Thank you Joanna and Milind for all the great evenings 
and support over the years. The week in Greece was amazing! Emma for all the nice chat 
about basically anything – even science sometimes! Thanks Maria for all those nice fika, and 
of course for basically taking me off the street. Christina for all the great fun and being such 
a good friend. Soaz for the great evenings and delicious crepes. Francesca for all the biscuits. 
  43 
Sara for the best cover idea ever, and all the great times with the “crew” from Science to 
Business (Kata, Alex, Öykü, Leo, Sabrina). Cynthia and Anna for ice-skating and fun in 
general. 
A general thank you to all my friends spread around Europe which took time to show me 
wonderful places and discover different cultures. In particular Pauline for interesting 
conversations about medicine and showing me Paris. Lilia for showing me Oslo and being so 
outspoken. And of course, thank you Marta for all the great times, and being so enthusiastic 
to show me the real Barcelona – I have unforgettable memories. I hope our paths cross again 
soon, but you’ll always be welcome wherever I go.  
Merci à tous mes amis au Québec qui prennent le temps quand je suis de retour. Sam, 
Nicolas et Alex, merci de toujours prendre le temps pour une bière (ou 2) quand je suis à 
Montréal. Alex et Anne-Marie également, ça fait toujours plaisir de vous voir! Maryves, 
Annie et En, dommage que je sois si loin, mais pharmacie ensemble c’était franchement 
cool. Merci Lorène pour toutes ces bonnes soirées à Québec : dommage que l’Arabie 
Saoudite soit si loin mais on va s’arranger! Et Minh-Tan avec tes nombreuses passions et 
discussions intéressantes.  
Un gros merci à toute ma famille qui m’a toujours supporté malgré la distance. Les réunions 
de famille au lac ou pour le jour de l’an me manquent beaucoup, et j’apprécie qu’on prenne le 
temps de se voir quand je suis de passage. Merci Papa pour ces beaux voyages en nature 
ensemble au Québec – mes passions pour la photographie et le plein air viennent de cela. 
Valérie, merci ma petite grande sœur qui m’inspire à voir la vie d’un point de vue original, et 
qui prend le temps de m’écouter parler de ma recherche et réexplique fièrement le tout à ses 
amis. Merci Maman et Cristian, en particulier pour la bonne bouffe et les bonnes soirées qui 
sont une source d’énergie inestimable quand je suis de retour. Et Lucia bien sûr, merci de 
tout cœur de m’avoir épaulé dans les moments les plus durs et pour tous tes conseils. J’espère 
que tu sais à quel point, malgré la distance, tu as contribué à mon succès. 
Finally, all of this wouldn’t have been possible without Margherita. We’ve met at the 
perfect time in my life, and since then, you have always been there to support me, even in the 
toughest times. Your family has been very nice with me and I would like to thank them all 
too (Paolo, Nicoletta, Francesco). Your support, both with the science and everything else, 
has made a huge difference. Thank you. 
  45 
5 REFERENCES 
1. Murphy, K.P., et al., Janeway's Immunobiology. 2008: Garland Science. 
2. Abbas, A.K. and A.H. Lichtman, Basic immunology : functions and disorders of the immune system. 
3rd ed. 2009, Philadelphia, PA: Saunders/Elsevier. viii, 312 p. 
3. Barnes, P.J., Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol, 
2008. 8(3): p. 183-92. 
4. Finn, O.J., Cancer immunology. N Engl J Med, 2008. 358(25): p. 2704-15. 
5. Park, J.E. and A. Barbul, Understanding the role of immune regulation in wound healing. Am J Surg, 
2004. 187(5A): p. 11S-16S. 
6. Ross, R., Atherosclerosis--an inflammatory disease. N Engl J Med, 1999. 340(2): p. 115-26. 
7. Hansson, G.K. and A. Hermansson, The immune system in atherosclerosis. Nat Immunol, 2011. 12(3): 
p. 204-12. 
8. Rosenberg, S.A., J.C. Yang, and N.P. Restifo, Cancer immunotherapy: moving beyond current 
vaccines. Nat Med, 2004. 10(9): p. 909-15. 
9. Gatti, R.A. and R.A. Good, Occurrence of malignancy in immunodeficiency diseases. A literature 
review. Cancer, 1971. 28(1): p. 89-98. 
10. Toruner, M., et al., Risk factors for opportunistic infections in patients with inflammatory bowel 
disease. Gastroenterology, 2008. 134(4): p. 929-36. 
11. Kaplan, J.E., et al., Guidelines for prevention and treatment of opportunistic infections in HIV-infected 
adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV 
Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep, 2009. 
58(RR-4): p. 1-207; quiz CE1-4. 
12. Anderson, J.M. and C.M. Van Itallie, Physiology and Function of the Tight Junction. Cold Spring 
Harbor Perspectives in Biology, 2009. 1(2). 
13. Nizet, V., et al., Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature, 
2001. 414(6862): p. 454-457. 
14. Artis, D., Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in 
the gut. Nature Reviews Immunology, 2008. 8(6): p. 411-420. 
15. Backhed, F., et al., Host-bacterial mutualism in the human intestine. Science, 2005. 307(5717): p. 
1915-1920. 
16. Ouwehand, A., E. Isolauri, and S. Salminen, The role of the intestinal microflora for the development of 
the immune system in early childhood. Eur J Nutr, 2002. 41 Suppl 1: p. I32-7. 
17. Kelly, D., S. Conway, and R. Aminov, Commensal gut bacteria: mechanisms of immune modulation. 
Trends Immunol, 2005. 26(6): p. 326-33. 
18. Round, J.L. and S.K. Mazmanian, The gut microbiota shapes intestinal immune responses during 
health and disease. Nature Reviews Immunology, 2009. 9(5): p. 313-323. 
19. Akira, S., S. Uematsu, and O. Takeuchi, Pathogen recognition and innate immunity. Cell, 2006. 124(4): 
p. 783-801. 
20. Lanier, L.L., NK cell recognition. Annual Review of Immunology, 2005. 23: p. 225-274. 
21. Bauer, S., et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. 
Science, 1999. 285(5428): p. 727-729. 
22. Lu, Y.C., W.C. Yeh, and P.S. Ohashi, LPS/TLR4 signal transduction pathway. Cytokine, 2008. 42(2): 
p. 145-51. 
23. Matzinger, P., Tolerance, danger, and the extended family. Annu Rev Immunol, 1994. 12: p. 991-1045. 
24. Bianchi, M.E., DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte 
Biology, 2007. 81(1): p. 1-5. 
25. Scaffidi, P., T. Misteli, and M.E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells 
triggers inflammation. Nature, 2002. 418(6894): p. 191-5. 
26. Harris, H.E., U. Andersson, and D.S. Pisetsky, HMGB1: a multifunctional alarmin driving autoimmune 
and inflammatory disease. Nat Rev Rheumatol, 2012. 8(4): p. 195-202. 
27. Netea, M.G., et al., An integrated model of the recognition of Candida albicans by the innate immune 
system. Nat Rev Microbiol, 2008. 6(1): p. 67-78. 
28. Cambi, A., et al., The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida 
albicans on dendritic cells. Eur J Immunol, 2003. 33(2): p. 532-8. 
 46 
29. Saijo, S., et al., Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is 
essential for host defense against Candida albicans. Immunity, 2010. 32(5): p. 681-91. 
30. Tada, H., et al., Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production 
of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent 
manner. Microbiol Immunol, 2002. 46(7): p. 503-12. 
31. Netea, M.G., et al., Immune sensing of Candida albicans requires cooperative recognition of mannans 
and glucans by lectin and Toll-like receptors. J Clin Invest, 2006. 116(6): p. 1642-50. 
32. Cambi, A., et al., Dendritic cell interaction with Candida albicans critically depends on N-linked 
mannan. J Biol Chem, 2008. 283(29): p. 20590-9. 
33. van de Veerdonk, F.L., et al., The macrophage mannose receptor induces IL-17 in response to Candida 
albicans. Cell Host Microbe, 2009. 5(4): p. 329-40. 
34. Sheng, K.C., et al., Mannan derivatives induce phenotypic and functional maturation of mouse 
dendritic cells. Immunology, 2006. 118(3): p. 372-83. 
35. Medzhitov, R., Toll-like receptors and innate immunity. Nat Rev Immunol, 2001. 1(2): p. 135-45. 
36. Takeuchi, O. and S. Akira, Pattern recognition receptors and inflammation. Cell, 2010. 140(6): p. 805-
20. 
37. Randolph, G.J., et al., Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. 
Immunity, 1999. 11(6): p. 753-761. 
38. Randolph, G.J., V. Angeli, and M.A. Swartz, Dendritic-cell trafficking to lymph nodes through 
lymphatic vessels. Nature Reviews Immunology, 2005. 5(8): p. 617-628. 
39. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity. Nature, 1998. 
392(6673): p. 245-252. 
40. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nat Rev 
Immunol, 2011. 11(11): p. 723-37. 
41. Gordon, S., Alternative activation of macrophages. Nat Rev Immunol, 2003. 3(1): p. 23-35. 
42. Mantovani, A., et al., Macrophage plasticity and polarization in tissue repair and remodelling. J 
Pathol, 2013. 229(2): p. 176-85. 
43. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage activation. Nat Rev 
Immunol, 2008. 8(12): p. 958-69. 
44. Mantovani, A., et al., The chemokine system in diverse forms of macrophage activation and 
polarization. Trends Immunol, 2004. 25(12): p. 677-86. 
45. Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012. 
122(3): p. 787-95. 
46. Lambeth, J.D., T. Kawahara, and B. Diebold, Regulation of Nox and Duox enzymatic activity and 
expression. Free Radic Biol Med, 2007. 43(3): p. 319-31. 
47. Wright, H.L., et al., Neutrophil function in inflammation and inflammatory diseases. Rheumatology 
(Oxford), 2010. 49(9): p. 1618-31. 
48. Witko-Sarsat, V., et al., Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest, 
2000. 80(5): p. 617-53. 
49. Borregaard, N., O.E. Sorensen, and K. Theilgaard-Monch, Neutrophil granules: a library of innate 
immunity proteins. Trends Immunol, 2007. 28(8): p. 340-5. 
50. Faurschou, M. and N. Borregaard, Neutrophil granules and secretory vesicles in inflammation. 
Microbes Infect, 2003. 5(14): p. 1317-27. 
51. El-Benna, J., P.M. Dang, and M.A. Gougerot-Pocidalo, Priming of the neutrophil NADPH oxidase 
activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin 
Immunopathol, 2008. 30(3): p. 279-89. 
52. Akgul, C., D.A. Moulding, and S.W. Edwards, Molecular control of neutrophil apoptosis. FEBS Lett, 
2001. 487(3): p. 318-22. 
53. Ward, C., et al., Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. 
Trends Pharmacol Sci, 1999. 20(12): p. 503-9. 
54. D'Autreaux, B. and M.B. Toledano, ROS as signalling molecules: mechanisms that generate specificity 
in ROS homeostasis. Nat Rev Mol Cell Biol, 2007. 8(10): p. 813-24. 
55. Trachootham, D., J. Alexandre, and P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a 
radical therapeutic approach? Nat Rev Drug Discov, 2009. 8(7): p. 579-91. 
  47 
56. Bedard, K. and K.H. Krause, The NOX family of ROS-generating NADPH oxidases: physiology and 
pathophysiology. Physiol Rev, 2007. 87(1): p. 245-313. 
57. Lambeth, J.D., NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol, 2004. 4(3): p. 181-
9. 
58. Sareila, O., et al., Identification of a region in p47phox/NCF1 crucial for phagocytic NADPH oxidase 
(NOX2) activation. J Leukoc Biol, 2013. 93(3): p. 427-35. 
59. Sallusto, F., J. Geginat, and A. Lanzavecchia, Central memory and effector memory T cell subsets: 
function, generation, and maintenance. Annu Rev Immunol, 2004. 22: p. 745-63. 
60. Schmitt, T.M. and J.C. Zuniga-Pflucker, Induction of T cell development from hematopoietic 
progenitor cells by delta-like-1 in vitro. Immunity, 2002. 17(6): p. 749-56. 
61. Surh, C.D. and J. Sprent, T-cell apoptosis detected in situ during positive and negative selection in the 
thymus. Nature, 1994. 372(6501): p. 100-3. 
62. Shortman, K., et al., The generation and fate of thymocytes. Semin Immunol, 1990. 2(1): p. 3-12. 
63. Schatz, D.G., V(D)J recombination. Immunol Rev, 2004. 200: p. 5-11. 
64. Turner, S.J., et al., Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol, 
2006. 6(12): p. 883-94. 
65. Benedict, C.L., et al., Terminal deoxynucleotidyl transferase and repertoire development. 
Immunological Reviews, 2000. 175: p. 150-157. 
66. Cabaniols, J.P., et al., Most alpha/beta T cell receptor diversity is due to terminal deoxynucleotidyl 
transferase. Journal of Experimental Medicine, 2001. 194(9): p. 1385-1390. 
67. Fugmann, S.D., et al., The RAG proteins and V(D)J recombination: complexes, ends, and transposition. 
Annu Rev Immunol, 2000. 18: p. 495-527. 
68. Oettinger, M.A., et al., Rag-1 and Rag-2, Adjacent Genes That Synergistically Activate V(D)J 
Recombination. Science, 1990. 248(4962): p. 1517-1523. 
69. Kawano, T., et al., CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by 
glycosylceramides. Science, 1997. 278(5343): p. 1626-9. 
70. Shinkai, Y., et al., RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J 
rearrangement. Cell, 1992. 68(5): p. 855-67. 
71. Brownlie, R.J. and R. Zamoyska, T cell receptor signalling networks: branched, diversified and 
bounded. Nat Rev Immunol, 2013. 13(4): p. 257-69. 
72. Clevers, H., et al., The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol, 
1988. 6: p. 629-62. 
73. Rudolph, M.G., R.L. Stanfield, and I.A. Wilson, How TCRs bind MHCs, peptides, and coreceptors. 
Annu Rev Immunol, 2006. 24: p. 419-66. 
74. Kim, P.W., et al., A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8. Science, 2003. 
301(5640): p. 1725-8. 
75. van Oers, N.S., N. Killeen, and A. Weiss, Lck regulates the tyrosine phosphorylation of the T cell 
receptor subunits and ZAP-70 in murine thymocytes. J Exp Med, 1996. 183(3): p. 1053-62. 
76. Chan, A.C., et al., The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor 
stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci U S A, 
1991. 88(20): p. 9166-70. 
77. Palacios, E.H. and A. Weiss, Distinct roles for Syk and ZAP-70 during early thymocyte development. J 
Exp Med, 2007. 204(7): p. 1703-15. 
78. Wang, H., et al., ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol, 2010. 
2(5): p. a002279. 
79. Elder, M.E., et al., Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell 
tyrosine kinase. Science, 1994. 264(5165): p. 1596-9. 
80. Negishi, I., et al., Essential Role for Zap-70 in Both Positive and Negative Selection of Thymocytes. 
Nature, 1995. 376(6539): p. 435-438. 
81. Vivier, E., J.A. Nunes, and F. Vely, Natural killer cell signaling pathways. Science, 2004. 306(5701): 
p. 1517-9. 
82. Scielzo, C., et al., ZAP-70 is expressed by normal and malignant human B-cell subsets of different 
maturational stage. Leukemia, 2006. 20(4): p. 689-95. 
83. Chen, L., et al., Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic 
lymphocytic leukemia. Blood, 2002. 100(13): p. 4609-14. 
 48 
84. Takata, M., et al., Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization 
through distinct pathways. EMBO J, 1994. 13(6): p. 1341-9. 
85. Colucci, F., et al., Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat 
Immunol, 2002. 3(3): p. 288-94. 
86. Starr, T.K., S.C. Jameson, and K.A. Hogquist, Positive and negative selection of T cells. Annu Rev 
Immunol, 2003. 21: p. 139-76. 
87. Klein, L., et al., Positive and negative selection of the T cell repertoire: what thymocytes see (and don't 
see). Nat Rev Immunol, 2014. 14(6): p. 377-91. 
88. Germain, R.N., T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol, 2002. 2(5): 
p. 309-22. 
89. Klein, L., et al., Antigen presentation in the thymus for positive selection and central tolerance 
induction. Nat Rev Immunol, 2009. 9(12): p. 833-44. 
90. Palmer, E., Negative selection--clearing out the bad apples from the T-cell repertoire. Nat Rev 
Immunol, 2003. 3(5): p. 383-91. 
91. Kyewski, B. and L. Klein, A central role for central tolerance. Annu Rev Immunol, 2006. 24: p. 571-
606. 
92. Anderson, M.S., et al., Projection of an immunological self shadow within the thymus by the aire 
protein. Science, 2002. 298(5597): p. 1395-401. 
93. Artyomov, M.N., et al., CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck 
delivery. Proc Natl Acad Sci U S A, 2010. 107(39): p. 16916-21. 
94. Miceli, M.C. and J.R. Parnes, The roles of CD4 and CD8 in T cell activation. Semin Immunol, 1991. 
3(3): p. 133-41. 
95. Chen, L. and D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev 
Immunol, 2013. 13(4): p. 227-42. 
96. Sharpe, A.H. and G.J. Freeman, The B7-CD28 superfamily. Nat Rev Immunol, 2002. 2(2): p. 116-26. 
97. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012. 
12(4): p. 252-64. 
98. Curtsinger, J.M. and M.F. Mescher, Inflammatory cytokines as a third signal for T cell activation. Curr 
Opin Immunol, 2010. 22(3): p. 333-40. 
99. Curtsinger, J.M., et al., Inflammatory cytokines provide a third signal for activation of naive CD4+ and 
CD8+ T cells. J Immunol, 1999. 162(6): p. 3256-62. 
100. Bromley, S.K., et al., The immunological synapse and CD28-CD80 interactions. Nat Immunol, 2001. 
2(12): p. 1159-66. 
101. Grakoui, A., et al., The immunological synapse: a molecular machine controlling T cell activation. 
Science, 1999. 285(5425): p. 221-7. 
102. Huppa, J.B. and M.M. Davis, T-cell-antigen recognition and the immunological synapse. Nat Rev 
Immunol, 2003. 3(12): p. 973-83. 
103. Vogt, A.B., S. Spindeldreher, and H. Kropshofer, Clustering of MHC-peptide complexes prior to their 
engagement in the immunological synapse: lipid raft and tetraspan microdomains. Immunol Rev, 
2002. 189: p. 136-51. 
104. Zou, W. and N.P. Restifo, T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol, 
2010. 10(4): p. 248-56. 
105. Swain, S.L., K.K. McKinstry, and T.M. Strutt, Expanding roles for CD4(+) T cells in immunity to 
viruses. Nat Rev Immunol, 2012. 12(2): p. 136-48. 
106. Zhu, J. and W.E. Paul, Heterogeneity and plasticity of T helper cells. Cell Res, 2010. 20(1): p. 4-12. 
107. Szabo, S.J., et al., Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol, 
2003. 21: p. 713-58. 
108. Romagnani, S., The Th1/Th2 paradigm. Immunol Today, 1997. 18(6): p. 263-6. 
109. Ansel, K.M., et al., Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol, 
2006. 24: p. 607-56. 
110. Constant, S.L. and K. Bottomly, Induction of Th1 and Th2 CD4+ T cell responses: the alternative 
approaches. Annu Rev Immunol, 1997. 15: p. 297-322. 
111. Licona-Limon, P., et al., TH2, allergy and group 2 innate lymphoid cells. Nat Immunol, 2013. 14(6): p. 
536-42. 
  49 
112. Redecke, V., et al., Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and 
promotes experimental asthma. J Immunol, 2004. 172(5): p. 2739-43. 
113. Robinson, D.S., et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic 
asthma. N Engl J Med, 1992. 326(5): p. 298-304. 
114. Harrington, L.E., et al., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct 
from the T helper type 1 and 2 lineages. Nat Immunol, 2005. 6(11): p. 1123-32. 
115. Park, H., et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 
17. Nat Immunol, 2005. 6(11): p. 1133-41. 
116. Steinman, L., A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-
mediated tissue damage. Nat Med, 2007. 13(2): p. 139-45. 
117. Dardalhon, V., et al., Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun, 2008. 
31(3): p. 252-6. 
118. Codarri, L., et al., RORgammat drives production of the cytokine GM-CSF in helper T cells, which is 
essential for the effector phase of autoimmune neuroinflammation. Nat Immunol, 2011. 12(6): p. 560-7. 
119. Bettelli, E., et al., Induction and effector functions of T(H)17 cells. Nature, 2008. 453(7198): p. 1051-7. 
120. Stritesky, G.L., N. Yeh, and M.H. Kaplan, IL-23 promotes maintenance but not commitment to the 
Th17 lineage. J Immunol, 2008. 181(9): p. 5948-55. 
121. Pelletier, M., et al., Evidence for a cross-talk between human neutrophils and Th17 cells. Blood, 2010. 
115(2): p. 335-43. 
122. Laan, M., et al., Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J 
Immunol, 1999. 162(4): p. 2347-52. 
123. Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the transcription 
factor Foxp3. Science, 2003. 299(5609): p. 1057-61. 
124. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky, Foxp3 programs the development and function of 
CD4+CD25+ regulatory T cells. Nat Immunol, 2003. 4(4): p. 330-6. 
125. Curotto de Lafaille, M.A. and J.J. Lafaille, Natural and adaptive foxp3+ regulatory T cells: more of the 
same or a division of labor? Immunity, 2009. 30(5): p. 626-35. 
126. Wing, K. and S. Sakaguchi, Regulatory T cells exert checks and balances on self tolerance and 
autoimmunity. Nat Immunol, 2010. 11(1): p. 7-13. 
127. Sakaguchi, S., et al., Regulatory T cells: how do they suppress immune responses? Int Immunol, 2009. 
21(10): p. 1105-11. 
128. Levine, A.G., et al., Continuous requirement for the TCR in regulatory T cell function. Nat Immunol, 
2014. 15(11): p. 1070-8. 
129. Baumgart, D.C. and W.J. Sandborn, Crohn's disease. Lancet, 2012. 380(9853): p. 1590-605. 
130. Griffiths, C.E. and J.N. Barker, Pathogenesis and clinical features of psoriasis. Lancet, 2007. 
370(9583): p. 263-71. 
131. Scott, D.L., F. Wolfe, and T.W. Huizinga, Rheumatoid arthritis. Lancet, 2010. 376(9746): p. 1094-108. 
132. Atkinson, M.A., G.S. Eisenbarth, and A.W. Michels, Type 1 diabetes. Lancet, 2014. 383(9911): p. 69-
82. 
133. Compston, A. and A. Coles, Multiple sclerosis. Lancet, 2008. 372(9648): p. 1502-17. 
134. Nestle, F.O., D.H. Kaplan, and J. Barker, Psoriasis. N Engl J Med, 2009. 361(5): p. 496-509. 
135. Tsoi, L.C., et al., Identification of 15 new psoriasis susceptibility loci highlights the role of innate 
immunity. Nat Genet, 2012. 44(12): p. 1341-8. 
136. Genetic Analysis of Psoriasis, C., et al., A genome-wide association study identifies new psoriasis 
susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet, 2010. 42(11): p. 985-90. 
137. Chandran, V. and S.P. Raychaudhuri, Geoepidemiology and environmental factors of psoriasis and 
psoriatic arthritis. J Autoimmun, 2010. 34(3): p. J314-21. 
138. Gladman, D.D., et al., Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann 
Rheum Dis, 2005. 64 Suppl 2: p. ii14-7. 
139. Alamanos, Y., P.V. Voulgari, and A.A. Drosos, Incidence and prevalence of psoriatic arthritis: a 
systematic review. J Rheumatol, 2008. 35(7): p. 1354-8. 
140. Langley, R.G., G.G. Krueger, and C.E. Griffiths, Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis, 2005. 64 Suppl 2: p. ii18-23; discussion ii24-5. 
141. Christophers, E., Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol, 2001. 26(4): p. 
314-20. 
 50 
142. Henseler, T. and E. Christophers, Psoriasis of early and late onset: characterization of two types of 
psoriasis vulgaris. J Am Acad Dermatol, 1985. 13(3): p. 450-6. 
143. Ferrandiz, C., et al., Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J 
Am Acad Dermatol, 2002. 46(6): p. 867-73. 
144. Bowcock, A.M. and J.N. Barker, Genetics of psoriasis: the potential impact on new therapies. J Am 
Acad Dermatol, 2003. 49(2 Suppl): p. S51-6. 
145. Abele, D.C., R.L. Dobson, and J.B. Graham, Heredity and Psoriasis. Study of a Large Family. Arch 
Dermatol, 1963. 88: p. 38-47. 
146. Duffy, D.L., L.S. Spelman, and N.G. Martin, Psoriasis in Australian twins. J Am Acad Dermatol, 1993. 
29(3): p. 428-34. 
147. Lonnberg, A.S., et al., Heritability of psoriasis in a large twin sample. Br J Dermatol, 2013. 169(2): p. 
412-6. 
148. Stuart, P.E., et al., Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat 
Genet, 2010. 42(11): p. 1000-4. 
149. Roberson, E.D. and A.M. Bowcock, Psoriasis genetics: breaking the barrier. Trends Genet, 2010. 
26(9): p. 415-23. 
150. Nair, R.P., et al., Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to 
HLA-C. American Journal of Human Genetics, 2000. 66(6): p. 1833-1844. 
151. Nair, R.P., et al., Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 
gene. American Journal of Human Genetics, 2006. 78(5): p. 827-851. 
152. Cargill, M., et al., A large-scale genetic association study confirms IL12B and leads to the 
identification of IL23R as psoriasis-risk genes. American Journal of Human Genetics, 2007. 80(2): p. 
273-290. 
153. Nair, R.P., et al., Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. Journal 
of Investigative Dermatology, 2008. 128(7): p. 1653-1661. 
154. Johnston, A., et al., Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in 
psoriasis. Human Molecular Genetics, 2013. 22(9): p. 1807-1815. 
155. Di Cesare, A., P. Di Meglio, and F.O. Nestle, The IL-23/Th17 Axis in the Immunopathogenesis of 
Psoriasis. Journal of Investigative Dermatology, 2009. 129(6): p. 1339-1350. 
156. Smith, R.L., et al., Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. 
Br J Dermatol, 2008. 158(5): p. 962-8. 
157. Li, Y.H., et al., Further Genetic Evidence for Three Psoriasis-Risk Genes: ADAM33, CDKAL1, and 
PTPN22. Journal of Investigative Dermatology, 2009. 129(3): p. 629-634. 
158. Harper, E.G., et al., Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: 
Implications for Psoriasis Pathogenesis. Journal of Investigative Dermatology, 2009. 129(9): p. 2175-
2183. 
159. Mckay, I.A. and I.M. Leigh, Altered Keratinocyte Growth and Differentiation in Psoriasis. Clinics in 
Dermatology, 1995. 13(2): p. 105-&. 
160. Nickoloff, B.J. and Y. Naidu, Perturbation of Epidermal Barrier Function Correlates with Initiation of 
Cytokine Cascade in Human Skin. Journal of the American Academy of Dermatology, 1994. 30(4): p. 
535-546. 
161. Pinkus, H. and A.H. Mehregan, Primary Histologic Lesion of Seborrheic Dermatitis and Psoriasis. 
Journal of Investigative Dermatology, 1966. 46(1): p. 109-&. 
162. Leigh, I.M., et al., Keratins (K16 and K17) as Markers of Keratinocyte Hyperproliferation in Psoriasis 
in-Vivo and in-Vitro. British Journal of Dermatology, 1995. 133(4): p. 501-511. 
163. Truzzi, F., et al., A novel human psoriatic skin reconstruct: The role of transit amplifying keratinocytes 
and of p75 neurotrophin receptor. Journal of Investigative Dermatology, 2012. 132: p. S53-S53. 
164. Sabat, R., et al., Immunopathogenesis of psoriasis. Experimental Dermatology, 2007. 16(10): p. 779-
798. 
165. Kryczek, I., et al., Induction of IL-17(+) T cell trafficking and development by IFN-gamma: Mechanism 
and pathological relevance in psoriasis. Journal of Immunology, 2008. 181(7): p. 4733-4741. 
166. Boyman, O., et al., Spontaneous development of psoriasis in a new animal model shows an essential 
role for resident T cells and tumor necrosis factor-alpha. Journal of Experimental Medicine, 2004. 
199(5): p. 731-736. 
  51 
167. Nickoloff, B.J., et al., Severe Combined Immunodeficiency Mouse and Human Psoriatic Skin Chimeras 
- Validation of a New Animal-Model. American Journal of Pathology, 1995. 146(3): p. 580-588. 
168. Lebwohl, M., et al., A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New England 
Journal of Medicine, 2003. 349(21): p. 2004-2013. 
169. Ellis, C.N., et al., Cyclosporine Improves Psoriasis in a Double-Blind-Study. Jama-Journal of the 
American Medical Association, 1986. 256(22): p. 3110-3116. 
170. Schon, M., et al., Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky 
skin mice. Journal of Investigative Dermatology, 2000. 114(5): p. 976-983. 
171. Toichi, E., T. Tachibana, and F. Furukawa, Rapid improvement of psoriasis vulgaris during drug-
induced agranulocytosis. Journal of the American Academy of Dermatology, 2000. 43(2): p. 391-395. 
172. Heidenreich, R., M. Rocken, and K. Ghoreschi, Angiogenesis drives psoriasis pathogenesis. 
International Journal of Experimental Pathology, 2009. 90(3): p. 232-248. 
173. Guerard, S. and R. Pouliot, The role of angiogenesis in the pathogenesis of psoriasis: mechanisms and 
clinical implications. Journal of Clinical Dermatology Research, 2012. S4: p. 007. 
174. Henno, A., et al., Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved 
skin of plaque-type psoriasis. British Journal of Dermatology, 2009. 160(3): p. 581-590. 
175. Zhang, Y., H. Matsuo, and E. Morita, Vascular endothelial growth factor 121 is the predominant 
isoform in psoriatic scales. Experimental Dermatology, 2005. 14(10): p. 758-764. 
176. Detmar, M., et al., Overexpression of Vascular-Permeability Factor Vascular Endothelial Growth-
Factor and Its Receptors in Psoriasis. Journal of Experimental Medicine, 1994. 180(3): p. 1141-1146. 
177. Detmar, M., et al., Increased microvascular density and enhanced leukocyte rolling and adhesion in the 
skin of VEGF transgenic mice. Journal of Investigative Dermatology, 1998. 111(1): p. 1-6. 
178. Lowes, M.A., A.M. Bowcock, and J.G. Krueger, Pathogenesis and therapy of psoriasis. Nature, 2007. 
445(7130): p. 866-73. 
179. Gulliver, W., Long-term prognosis in patients with psoriasis. Br J Dermatol, 2008. 159 Suppl 2: p. 2-9. 
180. Choi, J. and J.Y. Koo, Quality of life issues in psoriasis. J Am Acad Dermatol, 2003. 49(2 Suppl): p. 
S57-61. 
181. Chaudhari, U., et al., Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a 
randomised trial. Lancet, 2001. 357(9271): p. 1842-7. 
182. Leonardi, C.L., et al., Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003. 
349(21): p. 2014-22. 
183. Langley, R.G., et al., Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med, 
2014. 371(4): p. 326-38. 
184. Papp, K.A., et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, 
in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial 
(PHOENIX 2). Lancet, 2008. 371(9625): p. 1675-84. 
185. Centers for Disease, C. and Prevention, National and state medical expenditures and lost earnings 
attributable to arthritis and other rheumatic conditions--United States, 2003. MMWR Morb Mortal 
Wkly Rep, 2007. 56(1): p. 4-7. 
186. Salaffi, F., et al., The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and 
psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes, 
2009. 7: p. 25. 
187. Zhang, W. and A.H. Anis, The economic burden of rheumatoid arthritis: beyond health care costs. Clin 
Rheumatol, 2011. 30 Suppl 1: p. S25-32. 
188. Stahl, E.A., et al., Genome-wide association study meta-analysis identifies seven new rheumatoid 
arthritis risk loci. Nat Genet, 2010. 42(6): p. 508-14. 
189. Okada, Y., et al., Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 
2014. 506(7488): p. 376-81. 
190. McInnes, I.B. and G. Schett, The pathogenesis of rheumatoid arthritis. N Engl J Med, 2011. 365(23): p. 
2205-19. 
191. Aletaha, D., et al., 2010 rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 2010. 
69(9): p. 1580-8. 
192. Schellekens, G.A., et al., The diagnostic properties of rheumatoid arthritis antibodies recognizing a 
cyclic citrullinated peptide. Arthritis Rheum, 2000. 43(1): p. 155-63. 
 52 
193. Schellekens, G.A., et al., Citrulline is an essential constituent of antigenic determinants recognized by 
rheumatoid arthritis-specific autoantibodies. J Clin Invest, 1998. 101(1): p. 273-81. 
194. Rantapaa-Dahlqvist, S., et al., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor 
predict the development of rheumatoid arthritis. Arthritis Rheum, 2003. 48(10): p. 2741-9. 
195. Nielen, M.M., et al., Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of 
serial measurements in blood donors. Arthritis Rheum, 2004. 50(2): p. 380-6. 
196. Kroot, E.J., et al., The prognostic value of anti-cyclic citrullinated peptide antibody in patients with 
recent-onset rheumatoid arthritis. Arthritis Rheum, 2000. 43(8): p. 1831-5. 
197. Meyer, O., et al., Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for 
predicting five year radiographic damage. Ann Rheum Dis, 2003. 62(2): p. 120-6. 
198. Kuhn, K.A., et al., Antibodies against citrullinated proteins enhance tissue injury in experimental 
autoimmune arthritis. J Clin Invest, 2006. 116(4): p. 961-73. 
199. Hill, J.A., et al., Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE 
transgenic mice. J Exp Med, 2008. 205(4): p. 967-79. 
200. Haag, S., et al., Human alpha-enolase is immunogenic, but not arthritogenic, in HLA-DR4-transgenic 
mice: comment on the article by Kinloch et al. Arthritis Rheum, 2012. 64(5): p. 1689-91; author reply 
1691-2. 
201. Padyukov, L., et al., A genome-wide association study suggests contrasting associations in ACPA-
positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis, 2011. 70(2): p. 259-65. 
202. van der Woude, D., et al., Quantitative heritability of anti-citrullinated protein antibody-positive and 
anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum, 2009. 60(4): p. 916-
23. 
203. Daha, N.A. and R.E. Toes, Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same 
disease? Nat Rev Rheumatol, 2011. 7(4): p. 202-3. 
204. Alamanos, Y. and A.A. Drosos, Epidemiology of adult rheumatoid arthritis. Autoimmun Rev, 2005. 
4(3): p. 130-6. 
205. Ferucci, E.D., D.W. Templin, and A.P. Lanier, Rheumatoid arthritis in American Indians and Alaska 
Natives: a review of the literature. Semin Arthritis Rheum, 2005. 34(4): p. 662-7. 
206. Kvien, T.K., et al., Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci, 
2006. 1069: p. 212-22. 
207. Goemaere, S., et al., Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal 
transition. J Rheumatol, 1990. 17(12): p. 1620-2. 
208. van der Woude, D., et al., Epitope spreading of the anti-citrullinated protein antibody response occurs 
before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis, 2010. 
69(8): p. 1554-61. 
209. Brink, M., et al., Multiplex analyses of antibodies against citrullinated peptides in individuals prior to 
development of rheumatoid arthritis. Arthritis Rheum, 2013. 65(4): p. 899-910. 
210. MacGregor, A.J., et al., Characterizing the quantitative genetic contribution to rheumatoid arthritis 
using data from twins. Arthritis Rheum, 2000. 43(1): p. 30-7. 
211. Silman, A.J., et al., Twin concordance rates for rheumatoid arthritis: results from a nationwide study. 
Br J Rheumatol, 1993. 32(10): p. 903-7. 
212. Aho, K., et al., Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol, 1986. 
13(5): p. 899-902. 
213. Okada, Y., et al., Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the 
Japanese population. Nat Genet, 2012. 44(5): p. 511-6. 
214. Weyand, C.M., et al., The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. 
Ann Intern Med, 1992. 117(10): p. 801-6. 
215. Holoshitz, J., The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol, 2010. 22(3): 
p. 293-8. 
216. Gregersen, P.K., J. Silver, and R.J. Winchester, The shared epitope hypothesis. An approach to 
understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum, 1987. 
30(11): p. 1205-13. 
217. Huizinga, T.W., et al., Refining the complex rheumatoid arthritis phenotype based on specificity of the 
HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum, 2005. 52(11): p. 
3433-8. 
  53 
218. van der Helm-van Mil, A.H., et al., The HLA-DRB1 shared epitope alleles are primarily a risk factor 
for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development 
of rheumatoid arthritis. Arthritis Rheum, 2006. 54(4): p. 1117-21. 
219. van Gaalen, F.A., et al., Association between HLA class II genes and autoantibodies to cyclic 
citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum, 2004. 
50(7): p. 2113-21. 
220. Hill, J.A., et al., Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide 
interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J 
Immunol, 2003. 171(2): p. 538-41. 
221. Viatte, S., D. Plant, and S. Raychaudhuri, Genetics and epigenetics of rheumatoid arthritis. Nat Rev 
Rheumatol, 2013. 9(3): p. 141-53. 
222. Rieck, M., et al., Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. 
J Immunol, 2007. 179(7): p. 4704-10. 
223. Stanford, S.M. and N. Bottini, PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev 
Rheumatol, 2014. 10(10): p. 602-11. 
224. Gregersen, P.K., Gaining insight into PTPN22 and autoimmunity. Nat Genet, 2005. 37(12): p. 1300-2. 
225. Vang, T., et al., Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. 
Nat Genet, 2005. 37(12): p. 1317-9. 
226. Lee, Y.H., et al., The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-
analysis. Rheumatology (Oxford), 2007. 46(1): p. 49-56. 
227. Gregersen, P.K., et al., PTPN22: setting thresholds for autoimmunity. Semin Immunol, 2006. 18(4): p. 
214-23. 
228. Menard, L., et al., The PTPN22 allele encoding an R620W variant interferes with the removal of 
developing autoreactive B cells in humans. J Clin Invest, 2011. 121(9): p. 3635-44. 
229. Habib, T., et al., Altered B cell homeostasis is associated with type I diabetes and carriers of the 
PTPN22 allelic variant. J Immunol, 2012. 188(1): p. 487-96. 
230. Arechiga, A.F., et al., Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs 
B cell signaling. J Immunol, 2009. 182(6): p. 3343-7. 
231. Bottini, N., et al., A functional variant of lymphoid tyrosine phosphatase is associated with type I 
diabetes. Nat Genet, 2004. 36(4): p. 337-8. 
232. Begovich, A.B., et al., A missense single-nucleotide polymorphism in a gene encoding a protein 
tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet, 2004. 75(2): 
p. 330-7. 
233. Kyogoku, C., et al., Genetic association of the R620W polymorphism of protein tyrosine phosphatase 
PTPN22 with human SLE. Am J Hum Genet, 2004. 75(3): p. 504-7. 
234. Velaga, M.R., et al., The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene 
is a major determinant of Graves' disease. J Clin Endocrinol Metab, 2004. 89(11): p. 5862-5. 
235. Heliovaara, M., et al., Smoking and Risk of Rheumatoid-Arthritis. Journal of Rheumatology, 1993. 
20(11): p. 1830-1835. 
236. Vessey, M.P., L. Villard-Mackintosh, and D. Yeates, Oral contraceptives, cigarette smoking and other 
factors in relation to arthritis. Contraception, 1987. 35(5): p. 457-64. 
237. Uhlig, T., K.B. Hagen, and T.K. Kvien, Current tobacco smoking, formal education, and the risk of 
rheumatoid arthritis. J Rheumatol, 1999. 26(1): p. 47-54. 
238. Karlson, E.W., et al., A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis 
in female health professionals. Arthritis Rheum, 1999. 42(5): p. 910-7. 
239. Silman, A.J., J. Newman, and A.J. MacGregor, Cigarette smoking increases the risk of rheumatoid 
arthritis - Results from a nationwide study of disease-discordant twins. Arthritis and Rheumatism, 
1996. 39(5): p. 732-735. 
240. Wolfe, F., The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid 
arthritis. J Rheumatol, 2000. 27(3): p. 630-7. 
241. Saag, K.G., et al., Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis, 1997. 56(8): p. 
463-9. 
242. Padyukov, L., et al., A gene-environment interaction between smoking and shared epitope genes in 
HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum, 2004. 50(10): p. 
3085-92. 
 54 
243. Linn-Rasker, S.P., et al., Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis 
patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis, 2006. 65(3): p. 366-71. 
244. Klareskog, L., et al., A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-
DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis 
Rheum, 2006. 54(1): p. 38-46. 
245. Makrygiannakis, D., et al., Smoking increases peptidylarginine deiminase 2 enzyme expression in 
human lungs and increases citrullination in BAL cells. Ann Rheum Dis, 2008. 67(10): p. 1488-92. 
246. Willemze, A., et al., The interaction between HLA shared epitope alleles and smoking and its 
contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum, 2011. 63(7): p. 
1823-32. 
247. Kallberg, H., et al., Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and 
smoking in two subsets of rheumatoid arthritis. Am J Hum Genet, 2007. 80(5): p. 867-75. 
248. Lee, H.S., et al., Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: 
a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum, 2007. 
56(6): p. 1745-53. 
249. Hensvold, A.H., et al., Environmental and genetic factors in the development of anticitrullinated 
protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation 
in twins. Ann Rheum Dis, 2015. 74(2): p. 375-80. 
250. Silman, A., A. Kay, and P. Brennan, Timing of pregnancy in relation to the onset of rheumatoid 
arthritis. Arthritis Rheum, 1992. 35(2): p. 152-5. 
251. Nelson, J.L. and M. Ostensen, Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am, 1997. 
23(1): p. 195-212. 
252. Wilder, R.L., Hormones, pregnancy, and autoimmune diseases. Ann N Y Acad Sci, 1998. 840: p. 45-
50. 
253. Spector, T.D. and M.C. Hochberg, The protective effect of the oral contraceptive pill on rheumatoid 
arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol, 
1990. 43(11): p. 1221-30. 
254. van Zeben, D., et al., Diminished incidence of severe rheumatoid arthritis associated with oral 
contraceptive use. Arthritis Rheum, 1990. 33(10): p. 1462-5. 
255. Vandenbroucke, J.P., et al., Oral contraceptives and rheumatoid arthritis: further evidence for a 
preventive effect. Lancet, 1982. 2(8303): p. 839-42. 
256. Jansson, L., T. Olsson, and R. Holmdahl, Estrogen induces a potent suppression of experimental 
autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol, 1994. 53(2): 
p. 203-7. 
257. Josefsson, E. and A. Tarkowski, Suppression of type II collagen-induced arthritis by the endogenous 
estrogen metabolite 2-methoxyestradiol. Arthritis Rheum, 1997. 40(1): p. 154-63. 
258. Holmdahl, R., L. Jansson, and M. Andersson, Female sex hormones suppress development of collagen-
induced arthritis in mice. Arthritis Rheum, 1986. 29(12): p. 1501-9. 
259. Hall, G.M., et al., A randomised controlled trial of the effect of hormone replacement therapy on 
disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis, 1994. 53(2): p. 112-6. 
260. D'Elia, H.F., et al., Influence of hormone replacement therapy on disease progression and bone mineral 
density in rheumatoid arthritis. J Rheumatol, 2003. 30(7): p. 1456-63. 
261. Ansar Ahmed, S., W.J. Penhale, and N. Talal, Sex hormones, immune responses, and autoimmune 
diseases. Mechanisms of sex hormone action. Am J Pathol, 1985. 121(3): p. 531-51. 
262. Jansson, L. and R. Holmdahl, Estrogen-mediated immunosuppression in autoimmune diseases. 
Inflamm Res, 1998. 47(7): p. 290-301. 
263. Polanczyk, M.J., et al., Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell 
compartment. J Immunol, 2004. 173(4): p. 2227-30. 
264. Beral, V., Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003. 
362(9382): p. 419-27. 
265. Wucherpfennig, K.W. and J.L. Strominger, Molecular mimicry in T cell-mediated autoimmunity: viral 
peptides activate human T cell clones specific for myelin basic protein. Cell, 1995. 80(5): p. 695-705. 
266. Albani, S. and D.A. Carson, A multistep molecular mimicry hypothesis for the pathogenesis of 
rheumatoid arthritis. Immunol Today, 1996. 17(10): p. 466-70. 
  55 
267. Cole, B.C. and M.M. Griffiths, Triggering and exacerbation of autoimmune arthritis by the 
Mycoplasma arthritidis superantigen MAM. Arthritis Rheum, 1993. 36(7): p. 994-1002. 
268. Benoist, C. and D. Mathis, Autoimmunity provoked by infection: how good is the case for T cell epitope 
mimicry? Nat Immunol, 2001. 2(9): p. 797-801. 
269. Ogrendik, M., Rheumatoid arthritis is linked to oral bacteria: etiological association. Mod Rheumatol, 
2009. 19(5): p. 453-6. 
270. Rosenstein, E.D., et al., Hypothesis: the humoral immune response to oral bacteria provides a stimulus 
for the development of rheumatoid arthritis. Inflammation, 2004. 28(6): p. 311-8. 
271. Kharlamova, N., et al., Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral 
Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology. Arthritis Rheumatol, 2016. 68(3): 
p. 604-13. 
272. Hitchon, C.A., et al., Antibodies to porphyromonas gingivalis are associated with anticitrullinated 
protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol, 2010. 37(6): p. 
1105-12. 
273. Singh, J.A., et al., 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid 
Arthritis. Arthritis Rheumatol, 2016. 68(1): p. 1-26. 
274. Cutolo, M., et al., Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum 
Dis, 2001. 60(8): p. 729-35. 
275. Segal, R., M. Yaron, and B. Tartakovsky, Methotrexate: mechanism of action in rheumatoid arthritis. 
Semin Arthritis Rheum, 1990. 20(3): p. 190-200. 
276. Taylor, P.C. and M. Feldmann, Anti-TNF biologic agents: still the therapy of choice for rheumatoid 
arthritis. Nat Rev Rheumatol, 2009. 5(10): p. 578-82. 
277. Lipsky, P.E., et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor 
Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 
2000. 343(22): p. 1594-602. 
278. Aggarwal, B.B., S.C. Gupta, and J.H. Kim, Historical perspectives on tumor necrosis factor and its 
superfamily: 25 years later, a golden journey. Blood, 2012. 119(3): p. 651-65. 
279. Hanauer, S.B., et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. 
Lancet, 2002. 359(9317): p. 1541-9. 
280. Wolfe, F. and K. Michaud, Biologic treatment of rheumatoid arthritis and the risk of malignancy: 
analyses from a large US observational study. Arthritis Rheum, 2007. 56(9): p. 2886-95. 
281. Askling, J., et al., Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis 
factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum, 
2009. 60(11): p. 3180-9. 
282. Mariette, X., et al., Malignancies associated with tumour necrosis factor inhibitors in registries and 
prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis, 2011. 
70(11): p. 1895-904. 
283. Kremer, J.M., et al., Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with 
fusion protein CTLA4Ig. N Engl J Med, 2003. 349(20): p. 1907-15. 
284. Genovese, M.C., et al., Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha 
inhibition. N Engl J Med, 2005. 353(11): p. 1114-23. 
285. Schiff, M., et al., Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, 
multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis 
and an inadequate response to methotrexate. Ann Rheum Dis, 2008. 67(8): p. 1096-103. 
286. Smolen, J.S., et al., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with 
rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 
2008. 371(9617): p. 987-97. 
287. Hirano, T., et al., Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid 
arthritis. Eur J Immunol, 1988. 18(11): p. 1797-801. 
288. Houssiau, F.A., et al., Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis 
and other inflammatory arthritides. Arthritis Rheum, 1988. 31(6): p. 784-8. 
289. Emery, P., et al., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients 
with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week 
multicentre randomised placebo-controlled trial. Ann Rheum Dis, 2008. 67(11): p. 1516-23. 
 56 
290. Zhou, L., et al., IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the 
IL-21 and IL-23 pathways. Nat Immunol, 2007. 8(9): p. 967-74. 
291. McGeachy, M.J., et al., TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and 
restrain T(H)-17 cell-mediated pathology. Nat Immunol, 2007. 8(12): p. 1390-7. 
292. Yen, D., et al., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and 
IL-6. J Clin Invest, 2006. 116(5): p. 1310-6. 
293. Eugster, H.P., et al., IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced 
autoimmune encephalomyelitis. Eur J Immunol, 1998. 28(7): p. 2178-87. 
294. Sims, J.E. and D.E. Smith, The IL-1 family: regulators of immunity. Nat Rev Immunol, 2010. 10(2): p. 
89-102. 
295. Cohen, S., et al., Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 
receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, 
randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 2002. 46(3): p. 614-24. 
296. Joosten, L.A., et al., IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II 
collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J 
Immunol, 1999. 163(9): p. 5049-55. 
297. Abramson, S.B. and A. Amin, Blocking the effects of IL-1 in rheumatoid arthritis protects bone and 
cartilage. Rheumatology (Oxford), 2002. 41(9): p. 972-80. 
298. Singh, J.A., et al., A network meta-analysis of randomized controlled trials of biologics for rheumatoid 
arthritis: a Cochrane overview. CMAJ, 2009. 181(11): p. 787-96. 
299. Singh, J.A., et al., Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med 
J, 2010. 128(5): p. 309-10. 
300. Cohen, S.B., et al., Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: 
Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating 
primary efficacy and safety at twenty-four weeks. Arthritis Rheum, 2006. 54(9): p. 2793-806. 
301. Edwards, J.C., et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid 
arthritis. N Engl J Med, 2004. 350(25): p. 2572-81. 
302. McLaughlin, P., et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed 
indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 1998. 
16(8): p. 2825-33. 
303. Coiffier, B., et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients 
with diffuse large-B-cell lymphoma. N Engl J Med, 2002. 346(4): p. 235-42. 
304. Gurcan, H.M., et al., A review of the current use of rituximab in autoimmune diseases. Int 
Immunopharmacol, 2009. 9(1): p. 10-25. 
305. Hawker, K., et al., Rituximab in patients with primary progressive multiple sclerosis: results of a 
randomized double-blind placebo-controlled multicenter trial. Ann Neurol, 2009. 66(4): p. 460-71. 
306. Looney, R.J., et al., B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II 
dose-escalation trial of rituximab. Arthritis Rheum, 2004. 50(8): p. 2580-9. 
307. Hegen, M., et al., Utility of animal models for identification of potential therapeutics for rheumatoid 
arthritis. Ann Rheum Dis, 2008. 67(11): p. 1505-15. 
308. Kollias, G., et al., Animal models for arthritis: innovative tools for prevention and treatment. Ann 
Rheum Dis, 2011. 70(8): p. 1357-62. 
309. Brand, D.D., K.A. Latham, and E.F. Rosloniec, Collagen-induced arthritis. Nat Protoc, 2007. 2(5): p. 
1269-75. 
310. Holmdahl, R., et al., Arthritis induced in rats with nonimmunogenic adjuvants as models for 
rheumatoid arthritis. Immunol Rev, 2001. 184: p. 184-202. 
311. Durie, F.H., R.A. Fava, and R.J. Noelle, Collagen-induced arthritis as a model of rheumatoid arthritis. 
Clin Immunol Immunopathol, 1994. 73(1): p. 11-8. 
312. Holmdahl, R., et al., The molecular pathogenesis of collagen-induced arthritis in mice--a model for 
rheumatoid arthritis. Ageing Res Rev, 2002. 1(1): p. 135-47. 
313. Wooley, P.H., et al., Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I 
region) linkage and antibody correlates. J Exp Med, 1981. 154(3): p. 688-700. 
314. Corthay, A., et al., Collagen-induced arthritis development requires alpha beta T cells but not gamma 
delta T cells: studies with T cell-deficient (TCR mutant) mice. Int Immunol, 1999. 11(7): p. 1065-73. 
  57 
315. Michaelsson, E., et al., Identification of an immunodominant type-II collagen peptide recognized by T 
cells in H-2q mice: self tolerance at the level of determinant selection. Eur J Immunol, 1992. 22(7): p. 
1819-25. 
316. Corthay, A., et al., Epitope glycosylation plays a critical role for T cell recognition of type II collagen 
in collagen-induced arthritis. Eur J Immunol, 1998. 28(8): p. 2580-90. 
317. Corthay, A., J. Backlund, and R. Holmdahl, Role of glycopeptide-specific T cells in collagen-induced 
arthritis: an example how post-translational modification of proteins may be involved in autoimmune 
disease. Ann Med, 2001. 33(7): p. 456-65. 
318. Holmdahl, R., et al., Incidence of arthritis and autoreactivity of anti-collagen antibodies after 
immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol, 1985. 
62(3): p. 639-46. 
319. Svensson, L., et al., B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin 
Exp Immunol, 1998. 111(3): p. 521-6. 
320. Stuart, J.M. and F.J. Dixon, Serum transfer of collagen-induced arthritis in mice. J Exp Med, 1983. 
158(2): p. 378-92. 
321. Alonzi, T., et al., Interleukin 6 is required for the development of collagen-induced arthritis. J Exp 
Med, 1998. 187(4): p. 461-8. 
322. van den Berg, W.B., et al., Amelioration of established murine collagen-induced arthritis with anti-IL-1 
treatment. Clin Exp Immunol, 1994. 95(2): p. 237-43. 
323. Williams, R.O., M. Feldmann, and R.N. Maini, Anti-tumor necrosis factor ameliorates joint disease in 
murine collagen-induced arthritis. Proc Natl Acad Sci U S A, 1992. 89(20): p. 9784-8. 
324. Webb, L.M., M.J. Walmsley, and M. Feldmann, Prevention and amelioration of collagen-induced 
arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J 
Immunol, 1996. 26(10): p. 2320-8. 
325. Rowley, M.J., K.S. Nandakumar, and R. Holmdahl, The role of collagen antibodies in mediating 
arthritis. Mod Rheumatol, 2008. 18(5): p. 429-41. 
326. Nandakumar, K.S., L. Svensson, and R. Holmdahl, Collagen type II-specific monoclonal antibody-
induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J 
Pathol, 2003. 163(5): p. 1827-37. 
327. Kagari, T., et al., Essential role of Fc gamma receptors in anti-type II collagen antibody-induced 
arthritis. J Immunol, 2003. 170(8): p. 4318-24. 
328. Tanaka, D., et al., Essential role of neutrophils in anti-type II collagen antibody and 
lipopolysaccharide-induced arthritis. Immunology, 2006. 119(2): p. 195-202. 
329. Nandakumar, K.S. and R. Holmdahl, Antibody-induced arthritis: disease mechanisms and genes 
involved at the effector phase of arthritis. Arthritis Res Ther, 2006. 8(6): p. 223. 
330. Hietala, M.A., et al., Complement activation by both classical and alternative pathways is critical for 
the effector phase of arthritis. Eur J Immunol, 2004. 34(4): p. 1208-16. 
331. Kagari, T., H. Doi, and T. Shimozato, The importance of IL-1 beta and TNF-alpha, and the 
noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol, 
2002. 169(3): p. 1459-66. 
332. Khachigian, L.M., Collagen antibody-induced arthritis. Nat Protoc, 2006. 1(5): p. 2512-6. 
333. Ditzel, H.J., The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med, 2004. 
10(1): p. 40-5. 
334. Iwanami, K., et al., Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of 
arthritis by glucose-6-phosphate isomerase. Arthritis Rheum, 2008. 58(3): p. 754-63. 
335. Bockermann, R., et al., Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate 
isomerase. Arthritis Res Ther, 2005. 7(6): p. R1316-24. 
336. Wipke, B.T. and P.M. Allen, Essential role of neutrophils in the initiation and progression of a murine 
model of rheumatoid arthritis. J Immunol, 2001. 167(3): p. 1601-8. 
337. Chen, M., et al., Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med, 
2006. 203(4): p. 837-42. 
338. Ji, H., et al., Arthritis critically dependent on innate immune system players. Immunity, 2002. 16(2): p. 
157-68. 
 58 
339. Vingsbo, C., et al., Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a 
chronic disease course influenced by both major histocompatibility complex and non-major 
histocompatibility complex genes. Am J Pathol, 1996. 149(5): p. 1675-83. 
340. Tuncel, J., et al., Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in the Rat. 
PLoS One, 2016. 11(5): p. e0155936. 
341. Stasiuk, L.M., et al., Pristane-induced arthritis is CD4+ T-cell dependent. Immunology, 1997. 90(1): p. 
81-6. 
342. Holmberg, J., et al., Pristane, a non-antigenic adjuvant, induces MHC class II-restricted, arthritogenic 
T cells in the rat. J Immunol, 2006. 176(2): p. 1172-9. 
343. Sakaguchi, N., et al., Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes 
autoimmune arthritis in mice. Nature, 2003. 426(6965): p. 454-60. 
344. Tanaka, S., et al., Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering 
thymic T cell selection and regulatory T cell function. J Immunol, 2010. 185(4): p. 2295-305. 
345. Nakamura, T., et al., Induction of autoimmune arthritis after direct injection of bone marrow cells from 
arthritis-prone SKG/Jcl mice into bone cavity of normal mice. Biol Pharm Bull, 2014. 37(11): p. 1719-
26. 
346. Hsu, L.Y., et al., A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune 
disease versus autoimmune reactivity. J Exp Med, 2009. 206(11): p. 2527-41. 
347. Zhao, W., et al., Analysis of accumulating clonotypes of T cell in joints of a spontaneous murine model 
of rheumatoid arthritis. Cell Mol Immunol, 2004. 1(4): p. 300-3. 
348. Wakasa-Morimoto, C., et al., Arthritis and pneumonitis produced by the same T cell clones from mice 
with spontaneous autoimmune arthritis. Int Immunol, 2008. 20(10): p. 1331-42. 
349. Ito, Y., et al., Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. 
Science, 2014. 346(6207): p. 363-8. 
350. Edwards, C.J. and C. Cooper, Early environmental factors and rheumatoid arthritis. Clin Exp 
Immunol, 2006. 143(1): p. 1-5. 
351. Yoshitomi, H., et al., A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of 
autoimmune arthritis in genetically susceptible mice. J Exp Med, 2005. 201(6): p. 949-60. 
352. Hashimoto, M., et al., Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J 
Exp Med, 2010. 207(6): p. 1135-43. 
353. Hida, S., et al., Cell wall beta-glucan derived from Candida albicans acts as a trigger for autoimmune 
arthritis in SKG mice. Biol Pharm Bull, 2007. 30(8): p. 1589-92. 
354. Ruutu, M., et al., beta-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. 
Arthritis Rheum, 2012. 64(7): p. 2211-22. 
355. Cutolo, M., et al., Sex hormones and rheumatoid arthritis. Autoimmun Rev, 2002. 1(5): p. 284-9. 
356. Lee, E.J., et al., Investigation of the relationship between the onset of arthritis and uveitis in genetically 
predisposed SKG mice. Arthritis Res Ther, 2015. 17: p. 218. 
357. Keith, R.C., et al., Testosterone is protective in the sexually dimorphic development of arthritis and 
lung disease in SKG mice. Arthritis Rheum, 2013. 65(6): p. 1487-93. 
358. Shaw, L.A., et al., Pregnancy amelioration of arthritis in SKG mice corresponds with alterations in 
serum amyloid A3 levels. Am J Clin Exp Immunol, 2012. 1(1): p. 12-19. 
359. Ostensen, M., Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. 
Ann N Y Acad Sci, 1999. 876: p. 131-43; discussion 144. 
360. Inoue, K., E. Inoue, and Y. Imai, Female sex hormones ameliorate arthritis in SKG mice. Biochem 
Biophys Res Commun, 2013. 434(4): p. 740-5. 
361. Caetano-Lopes, J., et al., Chronic arthritis leads to disturbances in the bone collagen network. Arthritis 
Res Ther, 2010. 12(1): p. R9. 
362. Caetano-Lopes, J., et al., Chronic arthritis directly induces quantitative and qualitative bone 
disturbances leading to compromised biomechanical properties. Clin Exp Rheumatol, 2009. 27(3): p. 
475-82. 
363. Keller, K.K., et al., Bone formation and resorption are both increased in experimental autoimmune 
arthritis. PLoS One, 2012. 7(12): p. e53034. 
364. Charles, J.F., et al., Inflammatory arthritis increases mouse osteoclast precursors with myeloid 
suppressor function. J Clin Invest, 2012. 122(12): p. 4592-605. 
  59 
365. Keller, K.K., et al., Systemic but no local effects of combined zoledronate and parathyroid hormone 
treatment in experimental autoimmune arthritis. PLoS One, 2014. 9(3): p. e92359. 
366. Keller, K.K., et al., SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with 
special focus on bone changes. Rheumatol Int, 2013. 33(5): p. 1127-33. 
367. Rehaume, L.M., et al., ZAP-70 genotype disrupts the relationship between microbiota and host, leading 
to spondyloarthritis and ileitis in SKG mice. Arthritis Rheumatol, 2014. 66(10): p. 2780-92. 
368. Benham, H., et al., Interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the 
development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol, 2014. 66(7): p. 1755-67. 
369. Shiomi, A., et al., GM-CSF but not IL-17 is critical for the development of severe interstitial lung 
disease in SKG mice. J Immunol, 2014. 193(2): p. 849-59. 
370. Keith, R.C., et al., A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG 
mice. Exp Lung Res, 2012. 38(2): p. 55-66. 
371. Khmaladze, I., et al., Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease 
in mice. Proc Natl Acad Sci U S A, 2014. 111(35): p. E3669-78. 
372. Choy, E.H. and G.S. Panayi, Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl 
J Med, 2001. 344(12): p. 907-16. 
373. Feldmann, M., Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol, 2002. 
2(5): p. 364-71. 
374. Hata, H., et al., Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated 
spontaneous autoimmune arthritis in mice. J Clin Invest, 2004. 114(4): p. 582-8. 
375. Kobayashi, K., et al., Cytokine production profile of splenocytes derived from zymosan A-treated SKG 
mice developing arthritis. Inflamm Res, 2006. 55(8): p. 335-41. 
376. Hirota, K., et al., T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ 
Th cells that cause autoimmune arthritis. J Exp Med, 2007. 204(1): p. 41-7. 
377. Ito, Y., et al., Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in 
collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum, 2009. 60(8): p. 2294-303. 
378. Wencker, M., et al., Innate-like T cells straddle innate and adaptive immunity by altering antigen-
receptor responsiveness. Nat Immunol, 2014. 15(1): p. 80-7. 
379. Hirota, K., et al., Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 
in rheumatoid arthritis and its animal model. J Exp Med, 2007. 204(12): p. 2803-12. 
380. Nishimura, K., et al., Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and 
ameliorates arthritis in SKG mice. Arthritis Rheumatol, 2015. 67(4): p. 893-902. 
381. Byun, J.K., et al., Rebamipide attenuates autoimmune arthritis severity in SKG mice via regulation of B 
cell and antibody production. Clin Exp Immunol, 2014. 178(1): p. 9-19. 
382. Murata, K., et al., MicroRNA-451 down-regulates neutrophil chemotaxis via p38 MAPK. Arthritis 
Rheumatol, 2014. 66(3): p. 549-59. 
383. Oh, K., et al., CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term 
Therapeutic Effects in an SKG Arthritis Model. Immune Netw, 2013. 13(6): p. 257-63. 
384. Tsunemi, S., et al., Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the 
treatment of rheumatoid arthritis. Arthritis Res Ther, 2013. 15(4): p. R75. 
385. Azuma, K., et al., Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse 
models. Inflammation, 2012. 35(4): p. 1462-5. 
386. Bahtiar, A., et al., The l-Ser analog #290 promotes bone recovery in OP and RA mice. Pharmacol Res, 
2011. 64(3): p. 203-9. 
387. Misaki, K., et al., Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic 
phenotype and ameliorates arthritis in SKG mice. Arthritis Res Ther, 2011. 13(3): p. R77. 
388. Duarte, J., et al., Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis 
in mice. PLoS One, 2010. 5(5): p. e10558. 
389. Tsunemi, S., et al., Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis 
model. Clin Immunol, 2010. 136(2): p. 197-204. 
390. Nagate, T., J. Kawai, and J. Nakayama, Therapeutic and preventive effects of methotrexate on zymosan-
induced arthritis in SKG mice. J Vet Med Sci, 2009. 71(6): p. 713-7. 
391. Mullazehi, M., et al., Anti-type II collagen antibodies are associated with early radiographic 
destruction in rheumatoid arthritis. Arthritis Res Ther, 2012. 14(3): p. R100. 
 60 
392. Cook, A.D., et al., Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease 
progression. Arthritis Rheum, 1996. 39(10): p. 1720-7. 
393. Fang, F.C., Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev 
Microbiol, 2004. 2(10): p. 820-32. 
394. Winkelstein, J.A., et al., Chronic granulomatous disease. Report on a national registry of 368 patients. 
Medicine (Baltimore), 2000. 79(3): p. 155-69. 
395. Olofsson, P., et al., Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. 
Nat Genet, 2003. 33(1): p. 25-32. 
396. Hultqvist, M., et al., Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced 
oxidative burst due to a mutation in the Ncf1 gene. Proc Natl Acad Sci U S A, 2004. 101(34): p. 12646-
51. 
397. van de Loo, F.A., et al., Deficiency of NADPH oxidase components p47phox and gp91phox caused 
granulomatous synovitis and increased connective tissue destruction in experimental arthritis models. 
Am J Pathol, 2003. 163(4): p. 1525-37. 
398. De Ravin, S.S., et al., Chronic granulomatous disease as a risk factor for autoimmune disease. J 
Allergy Clin Immunol, 2008. 122(6): p. 1097-103. 
399. Gelderman, K.A., et al., T cell surface redox levels determine T cell reactivity and arthritis 
susceptibility. Proc Natl Acad Sci U S A, 2006. 103(34): p. 12831-6. 
400. Hultqvist, M., et al., Lack of reactive oxygen species breaks T cell tolerance to collagen type II and 
allows development of arthritis in mice. J Immunol, 2007. 179(3): p. 1431-7. 
401. George-Chandy, A., et al., Th17 development and autoimmune arthritis in the absence of reactive 
oxygen species. Eur J Immunol, 2008. 38(4): p. 1118-26. 
402. Gelderman, K.A., et al., Macrophages suppress T cell responses and arthritis development in mice by 
producing reactive oxygen species. J Clin Invest, 2007. 117(10): p. 3020-8. 
403. Circu, M.L. and T.Y. Aw, Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic 
Biol Med, 2010. 48(6): p. 749-62. 
404. Simon, H.U., A. Haj-Yehia, and F. Levi-Schaffer, Role of reactive oxygen species (ROS) in apoptosis 
induction. Apoptosis, 2000. 5(5): p. 415-8. 
405. Zhang, Y., et al., ROS play a critical role in the differentiation of alternatively activated macrophages 
and the occurrence of tumor-associated macrophages. Cell Res, 2013. 23(7): p. 898-914. 
 
